CN111518207B

CN111518207B - Humanized anti-Abeta monoclonal antibody and application thereof

Info

Publication number: CN111518207B
Application number: CN201910104868.9A
Authority: CN
Inventors: 冯晓; 肖亮; 金磊; 孙大为; 梁阳秋; 刘爽; 王涛; 陈宇珩; 李正一; 刘淑芹
Original assignee: Changchun Genescience Pharmaceutical Co Ltd
Current assignee: Changchun Genescience Pharmaceutical Co Ltd
Priority date: 2019-02-01
Filing date: 2019-02-01
Publication date: 2022-03-29
Anticipated expiration: 2039-02-01
Also published as: CN111518207A; CN113508133B; CN113508133A; WO2020156220A1

Abstract

The invention relates to the technical field of antibody medicines, in particular to a humanized anti-Abeta monoclonal antibody and application thereof. The humanized anti-A beta monoclonal antibody provided by the invention can promote phagocytosis of A beta by macrophages, protect nerve cells from toxicity of A beta, has a certain effect of improving cognitive learning and memory capacity of mice in an Alzheimer dementia model, and can be used for treating and diagnosing diseases and symptoms related to amyloidosis, such as Alzheimer disease.

Description

Humanized anti-Abeta monoclonal antibody and application thereof

Technical Field

The invention relates to the technical field of antibody medicines, in particular to a humanized anti-Abeta monoclonal antibody and application thereof.

Background

Aβ

Amyloid beta (a β) is encoded by the human chromosome 21 gene, contains 39-43 amino acids, is in a β -sheet structure, is hydrophobic, and has a molecular weight of 4 KDa. A beta is derived from residue polypeptide generated by proteolytic enzyme cleavage of Amyloid Precursor Protein (APP). APP can be decomposed by alpha, beta and gamma-protease, and the decomposed products have different biological functions. Wherein the sequential action of the beta-protease and the gamma-protease produces A beta. Gamma-proteases generate the C-terminus of a β, which cleaves at the APP transmembrane region and can then generate a large number of 39-43 amino acid residue isoforms. The most common of all residue subtypes is A β₄₀And Abeta₄₂. The former is typically formed by cleavage of APP at the endoplasmic reticulum, while the latter is formed across the Golgi network.

Pathological mechanism of Abeta

It is now known that all nerve cells in the Central Nervous System (CNS), including neurons, astrocytes, microglia and endothelial cells, express APP and produce a β. Under normal physiological conditions, APP is hydrolyzed by α -secretase to produce a soluble sAPP α fragment. This fragment contains the extracellular region of APP and the 83 amino acid C-terminus located on the envelope. sAPP α can regulate neuronal excitability, improve synaptic plasticity, learning and memory, and enhance neuronal resistance to oxidative and metabolic stress. Under neuropathological conditions, APP is first hydrolyzed by β -secretase 1(BACE) to produce a fragment of sAPP β and a cell membrane-bound 99 amino acid peptide (C99). Subsequently, the C99 peptide fragment was acted upon by γ -secretase to produce a β. Unlike sappa α, a β causes loss of neurosynaptic function, decreases neuronal plasticity, changes in cellular energy metabolism, induces oxidative stress and mitochondrial dysfunction, thereby causing intracellular calcium imbalance. The formation, aggregation and deposition of a β, and in particular a β 42, can trigger neurotoxic and neurodegenerative diseases, and is also an important ring in the pathogenesis of Alzheimer's Disease (AD).

Ass and Alzheimer's Disease (AD)

A beta is one of main pathological marker proteins in the brain of Alzheimer's disease, and the formation, deposition and degradation of the A beta run through the whole pathological process of AD. The A beta is divided into soluble A beta and insoluble A beta, the soluble A beta is not neurotoxic, the soluble A beta has a neurocytotoxicity effect after the beta-folding to form filamentous fiber aggregates which are changed into insoluble precipitates, and the primary structure of the human A beta is a determining factor of the neurocytotoxicity effect. According to the literature, the neurotoxicity of a β is mainly reflected in the following 4 aspects: cholinergic neuronal damage, neuronal apoptosis, peroxidative damage and inflammatory responses.

1. Cholinergic neuronal injury

Massive damage and loss of neurons and synapses of the cholinergic system of the anterior basal zone, which project into the hippocampus and cortex, are the major causes of memory and cognitive decline in AD patients. The A beta activates protein kinase GSK-3/glycogen synthase kinase-3 beta, tau protein and mitochondrial pyruvate dehydrogenase are phosphorylated, enzyme activity is reduced, conversion of pyruvate into acetyl coenzyme A (acyl coenzyme A) is reduced, so that acetylcholine (ACh) synthesis is reduced, succinate dehydrogenase is inhibited, energy supply is reduced, cholinergic neuron and synapse damage, degeneration, transmitter transmission disorder are caused, and cholinergic system activity is reduced. The decrease in ACh, in turn, leads to increased production of a β, which in turn, leads to the formation of a vicious circle.

2. Apoptosis of nerve cells

The main hallmark of AD is a reduction in the number of neurons in the cortex and hippocampus. When A beta is gathered into a beta-sheet layer folding structure, the neurotoxicity is obviously enhanced, and the nerve cell apoptosis can be induced. This is an important cause of selective neuronal and synaptic deficits in AD. The fibrillar aggregated A beta interacts and cross-links with transmembrane receptors such as APP on the cell surface through a secretion pathway, so that the inhibition and abnormal activation of a signal transduction pathway are caused, and a nerve cell death program is started. Ca in A beta-induced environment²⁺Imbalances in stimulation of NMDA receptors or by damage of free radicals lead to changes in membrane permeability, Ca²⁺Influx causes glutamate receptor activation, which leads to hyperactivation of glutamatergic neurons and death. In addition, A β can also cause increased NO synthesis leading to nerve cellsAnd (5) apoptosis.

3. Damage by peroxidation

A β can cause oxidative stress in a variety of ways. The induction of increased free radicals by a β is an important cause of oxidative stress. The toxicity of A β is through H₂O₂Mediated, A β increases H in vivo via the Receptor for Advanced Glycation Endproducts (RAGE)₂O₂To produce oxidative damage, causing cell death. In addition, oxygen stress proliferates microglia, migrating along a β concentration gradient, causing microglia around senile plaques to aggregate, forming neuritic plaques, producing more reactive oxygen radicals. A β may also increase lipid peroxidation, H₂O₂Not only is a source of hydroxyl free radical, but also increases the abnormal expression of fast response transcription Nuclear Factor (NF-kB) protein, generates nerve cell membrane damage and leads to the degeneration of neurons.

4. Inflammatory reaction

There is an inflammatory response in the brain of AD patients. Glia cell hyperplasia around plaques and neurofibrillary tangles, a β stimulates the release of a range of strongly neurotoxic inflammatory proteins, such as a β -activated astrocytes and microglia, to release inflammatory cytokines. Such as NO, interleukin-1 (IL-1, IL-1 can make cytoskeletal protein-neurofilament protein abnormal production, damage neuron function), interleukin-6 (IL-6, IL-6 increase the over-high gene expression of ADP, promote the formation of A beta, the A beta can induce the expression of microglia IL-6, form the vicious circle in AD immune pathological process), tumor necrosis factor-alpha (TNF-alpha, TNF-alpha participates in AD pathological process through the CNS most main apolipoprotein ApoE), gamma-interferon (gamma-IFN), beta-Antitrypsin (ACT), complement C1, C3 and chemotactic factor, adhesion factor, etc. Many inflammatory factors induce inflammatory reactions, promote free radical production, oxidative stress, and cause degeneration and necrosis of nerve cells.

Medicine for A beta target intervention and treatment mechanism

Based on the above, toxicity of a β to neurons is an important factor in the development of AD. Thus, by inhibiting a β production and accelerating its clearance, it will be possible to halt the AD disease process and alleviate the disease symptoms. Drugs currently being developed and used in clinical applications are also based on the mechanism of production and clearance of a β, and include the following components:

1. inhibition of beta-and gamma-secretase

Beta-secretase hydrolysis of APP is the initial stage of amyloid production. Inhibition of β -secretase activity, while inhibiting a β production, can cause major side effects. Since, in addition to APP, β -secretase has numerous substrates, the hydrolysis of which plays an important role in the plasticity of neurons and synapses within the nervous system. Clinically, inhibitors of β -secretase, such as E2609(clinical trial ID # NCT01600859), MK-8931(NCT01739348) and LY2886721(NCT01807026, NCT01561430) are able to reduce a β levels in human cerebrospinal fluid by 80-90%, but no β -secretase inhibitors are currently on the market.

Gamma-secretase hydrolysis of APP is the last step in amyloid production, directly producing a β 40 and a β 42 fragments. Thus, inhibition of γ -secretase is also believed to be effective in inhibiting a β production for the treatment of AD. However, in addition to hydrolyzing APP, γ -secretase also hydrolyzes other substrate proteins, including Notch proteins. Notch proteins are important for cell proliferation, differentiation and intercellular signaling. Semagacestat (LY450139) was used as a gamma-secretase inhibitor in 3000 clinical trials (NCT00762411, NCT01035138, NCT 00762411). The results of the tests show that subjects experience not but no improvement but rather a worsening of cognition and are associated with side effects of weight loss, increased probability of skin cancer and high risk of infection. Other inhibitors of gamma-secretase, such as Avagacestat, also failed clinical trials (NCT00810147, NCT00890890, NCT00810147, NCT 01079819). Selective gamma-secretase modulators (SGSMs) can in theory avoid the side effects of total inhibition of gamma-secretase, inhibiting only the hydrolytic pathway of APP without interfering with other signaling pathways, such as the hydrolysis of Notch proteins. Some nonsteroidal anti-inflammatory drugs, such as ibuprofen, sulindac, indomethacin, and flurbiprofen, can modulate gamma-secretase levels and lower a β 42 levels in vitro and in vivo activity assays. Although this class of drugs has been shown to alleviate mild cognitive impairment and to reduce the levels of inflammatory factors in cerebrospinal fluid, the long-term use of non-steroidal anti-inflammatory drugs for the treatment of AD remains clinically proven.

2. Inhibiting the aggregation of A beta

Inhibition of the formation of age spots can be achieved by interfering with or antagonizing the aggregation of a β. Such as 3-amino-1-propanesulfonic acid (3-APS, alzheimer's, ramiprosate), inhibit a β aggregation by interfering with the interaction of tolerable a β and endogenous aminoglucans, which promote the formation and precipitation of a β amyloid fibers. However, phase III clinical trial results for 3-APS are not ideal, resulting in trial discontinuation. Other anti-a β aggregation drugs have also failed clinically in stages II and III, including Colostrinin, which inhibits a β aggregation and neutralizes a β neurotoxicity in vitro and improves mouse cognition in vivo, but have not achieved satisfactory results in phase II clinical trials. Scyllo-ino sito l (ELND005) is an oral drug against A.beta.aggregation and mouse experiments have shown that Scyllo-inositol can reduce A.beta.toxicity, but the expected effect was not achieved in phase II clinical trials for mild to moderate AD patients at 18 months.

3. Promoting A beta deposition and polymer removal

There are three major pathways for Α β deposition and polymer removal: activating the activity of amyloid plaque degrading enzymes; modulate the transport of a β in the brain and peripheral circulation and anti-a β immunotherapy.

A β deposits and polymers can be degraded by a variety of proteolytic enzymes, including plasmin, endothelin converting enzyme, angiotensin converting enzyme, metalloproteinases, and the like. These enzymes are present at low levels in the brain of AD patients, but due to the lack of specificity acting on these enzymes, no such drugs are currently in the clinic.

The transport of a β between the central nervous system and the peripheral circulatory system is regulated by apolipoproteins. Low density lipoprotein receptor-related protein (LRP-1) promotes the influx of A β from the brain into the blood. Receptor for advanced glycation end products (RAGE) may assist a β in crossing the blood brain barrier. The therapeutic mechanism is to reduce amyloid load in the brain by limiting the entry of a β into the peripheral circulation. To date, only inhibitors/modulators of RAGE have entered clinical trials, including PF-0449470052, which failed clinically in phase II, and TTP4000, which also had no reliable data indicating expected results in phase I clinical trials.

Anti-a β antibodies can neutralize a β toxicity and can improve the cognition in transgenic animals, and anti-a β antibodies have become popular for AD treatment. Anti-a β antibodies are primarily directed to early treatment of AD, as well as to mild to moderate AD treatment. This is also related to the pathogenic mechanism of a β, which is difficult to reverse and repair once neurons are injured, so early clearance of a β can be a more effective treatment and relief of AD.

4. A beta target antibody in clinical trial

There are currently 15 drugs of anti-a β antibodies in clinical trials, and in comparison, adacanaumab, ganteneumab and Solanezumab have progressed faster and have entered phase III clinics, and as mechanism-addressed, companies have localized the indications to mild senile dementia.

While there is currently some theoretical knowledge in the field of treating and preventing alzheimer's disease, there remains a need for improved compositions and methods for treating and/or preventing the disease, and a need exists for antibodies and treatments that are capable of targeting a β. Although there are some humanized monoclonal antibodies that are highly advantageous in terms of therapeutic treatment, it is at no time easy to screen for humanized monoclonal antibodies having the desired properties and functions, and there is still a pressing need for such humanized monoclonal antibodies in reality.

Disclosure of Invention

In view of the above, the technical problem to be solved by the present invention is to provide a humanized anti-a β monoclonal antibody and its application. And provides a vector of the nucleotide for coding the monoclonal antibody, a host cell and application thereof. The antibody gene variable region sequence can constitute full-length antibody molecule as medicine for clinical treatment and diagnosis of amyloidosis relative diseases and diseases, such as Alzheimer's disease.

In order to achieve the above object, the present invention provides the following technical solutions:

the present invention provides humanized anti-A beta monoclonal antibodies,

(I) the amino acid sequences of the three CDR regions of the heavy chain of the monoclonal antibody respectively have the amino acid sequences shown as

SEQ ID NO

1, 2 and 3; and (II) the amino acid sequences of the three CDR regions of the light chain of the monoclonal antibody have the amino acid sequences shown as

SEQ ID NO

4, 5 and 6 respectively;

or

(III), (I) or (II) the amino acid sequence obtained by substituting, deleting or adding one or more amino acids, and the amino acid sequence has the same function with the amino acid sequence of (I) or (II);

further, the functions are two or three functions of promoting phagocytosis of A beta by macrophages, improving cognitive learning and memory ability and cytotoxic protection activity of an Alzheimer dementia model;

or

(IV) an amino acid sequence having a homology of 97% or more with the amino acid sequence of (I), (II) or (III).

Furthermore, the epitope of the monoclonal antibody is Abeta_1～16；

In some embodiments of the invention, the invention provides humanized anti-a β monoclonal antibodies:

the heavy chain comprises three CDR regions, wherein the amino acid sequence of at least one CDR region has the amino acid sequence shown as SEQ ID NO. 1, 2 or 3, or has the amino acid sequence with more than 97 percent of sequence homology with the CDR region;

the light chain comprises three CDR regions, wherein the amino acid sequence of at least one CDR region has the amino acid sequence shown in SEQ ID NO. 4, 5 or 6, or has the amino acid sequence with more than 97 percent of sequence homology with the CDR regions.

In some embodiments of the invention, the amino acid sequences of the three CDR regions of the heavy chain of the monoclonal antibody have the amino acid sequences shown in

SEQ ID NO

1, 2 and 3, respectively;

the amino acid sequences of the three CDR regions of the light chain of the monoclonal antibody have the amino acid sequences shown in

SEQ ID NO

4, 5 and 6 respectively.

Wherein, the sequence shown in SEQ ID NO. 1 is SYGMH;

the sequence shown as SEQ ID NO. 2 is MIWYDGTKKYYSDSVKG;

the sequence shown in SEQ ID NO. 3 is DRGIGTRHGPYFMDV;

the sequence shown in SEQ ID NO. 4 is HARHNVRSYL;

the sequence shown in SEQ ID NO. 5 is AASSQQR;

the sequence shown in SEQ ID NO. 6 is LQSFGTPLT.

In some embodiments of the invention, the monoclonal antibodies provided herein,

(V) the amino acid sequences of the 4 FR regions of the heavy chain of the monoclonal antibody have the amino acid sequences shown as SEQ ID NO:7, 8, 9 and 10, respectively; and (VI), the amino acid sequences of the 4 FR regions of the light chain of the monoclonal antibody have the amino acid sequences shown as SEQ ID NO. 11, 12, 13 and 14 respectively;

or

(VII), (V) or (VI) by substituting, deleting or adding one or more amino acids, and is functionally identical to the amino acid sequence (V) or (VI);

or

(VIII) an amino acid sequence having a homology of 97% or more with the amino acid sequence of (V), (VI) or (VII).

In some embodiments of the invention, the heavy chain comprises 4 FR regions wherein the amino acid sequence of at least one FR region has the amino acid sequence shown in SEQ ID NO 7, 8, 9 or 10, or an amino acid sequence with more than 97% homology thereto;

the light chain comprises 4 FR regions, wherein the amino acid sequence of at least one FR region has the amino acid sequence shown as SEQ ID NO. 11, 12, 13 or 14, or has the amino acid sequence with more than 97 percent of homology with the FR region.

In some embodiments of the invention, the amino acid sequences of the 4 FR regions of the heavy chain of the monoclonal antibody have the amino acid sequences shown as SEQ ID NO. 7, 8, 9 or 10, respectively, or amino acid sequences having more than 97% homology thereto;

the amino acid sequences of the 4 FR regions of the light chain of the monoclonal antibody respectively have the amino acid sequences shown in SEQ ID NO. 11, 12, 13 or 14, or have the amino acid sequences with over 97 percent of homology with the amino acid sequences.

Wherein the sequence shown in SEQ ID NO. 7 is QVQLVESGGGVVQPGRSLRLSCAASDFAFR;

the sequence shown as SEQ ID NO. 8 is WVRQAPGKGLEWVA;

the sequence shown as SEQ ID NO. 9 is RFTISRDNSKNTLYLQMNTLRAEDTAVYYCAR;

10 is WGKGTTVTVSS;

the sequence shown as SEQ ID NO. 11 is DIQMTQSPSSLSASVGDRVTITC;

the sequence shown as SEQ ID NO. 12 is WYQQKPGKAPKLLIY;

sequence GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC shown in SEQ ID NO. 13;

the sequence shown in SEQ ID NO. 14 is FGGGTKVEIK;

in some embodiments of the invention, the monoclonal antibody,

(IX) the heavy chain variable region has an amino acid sequence shown in any one of SEQ ID NO 15-19, and (X) the light chain variable region has an amino acid sequence shown in any one of SEQ ID NO 20-24;

or

(XI), (IX) or (X) by substitution, deletion or addition of one or more amino acids, and is functionally identical to the amino acid sequence of (IX) or (X);

or

(XII) or an amino acid sequence having a homology of 97% or more with the amino acid sequence described In (IX), (X) or (XI).

In some embodiments of the invention, the heavy chain variable region has an amino acid sequence as set forth in any one of SEQ ID NOs 15-19; the light chain variable region has an amino acid sequence shown in any one of SEQ ID NO 20-24.

In some embodiments of the invention, the humanized anti a β monoclonal antibody has:

a heavy chain variable region having an amino acid sequence of SEQ ID NO. 15,16,17,18,19 and a light chain variable region having an amino acid sequence of SEQ ID NO. 20;

a heavy chain variable region having an amino acid sequence of SEQ ID NO. 15,16,17,18,19 and a light chain variable region having an amino acid sequence of SEQ ID NO. 21;

a heavy chain variable region having an amino acid sequence of SEQ ID NO. 15,16,17,18,19 and a light chain variable region having an amino acid sequence of SEQ ID NO. 22;

a heavy chain variable region having an amino acid sequence of SEQ ID NO. 15,16,17,18,19 and a light chain variable region having an amino acid sequence of SEQ ID NO. 23;

a heavy chain variable region having an amino acid sequence of SEQ ID NO. 15,16,17,18,19 and a light chain variable region having an amino acid sequence of SEQ ID NO. 24;

in some embodiments of the invention, the monoclonal antibody,

(XIII) in which the heavy chain variable region has an amino acid sequence shown in SEQ ID NO:15 and the light chain variable region has an amino acid sequence shown in SEQ ID NO: 24;

or (XIV) the heavy chain variable region has the amino acid sequence shown as SEQ ID NO:16, and the light chain variable region has the amino acid sequence shown as SEQ ID NO: 22;

or (XV) the heavy chain variable region has the amino acid sequence shown in SEQ ID NO:16 and the light chain variable region has the amino acid sequence shown in SEQ ID NO: 24;

or (XVI) has the amino acid sequence shown in SEQ ID NO:17 in its heavy chain variable region and the amino acid sequence shown in SEQ ID NO:24 in its light chain variable region;

or (XVII) the heavy chain variable region has the amino acid sequence shown in SEQ ID NO:18, and the light chain variable region has the amino acid sequence shown in SEQ ID NO: 24;

or (XVIII) has the amino acid sequence shown in SEQ ID NO:19 in its heavy chain variable region and the amino acid sequence shown in SEQ ID NO:24 in its light chain variable region.

In the present invention, the sequence having at least 97% sequence homology is an amino acid sequence obtained by substituting, deleting or adding one or more amino acids based on the original sequence, and the plurality is 2, 3, 4 or 5.

The monoclonal antibody further comprises a constant region, wherein the constant region of the heavy chain of the monoclonal antibody is any one of human IgG1, IgG2, IgG3 or IgG 4; the constant region of the light chain of the monoclonal antibody is of the kappa type or of the lambda type.

The heavy chain constant region of the humanized anti-Abeta monoclonal antibody provided by the invention is human IgG1, and the light chain constant region is the constant region of a human kappa chain.

The humanized anti-Abeta monoclonal antibody provided by the invention can be combined with human Abeta; in certain embodiments, the affinity between an antibody and its target is characterized by Ka (binding constant), Kd (dissociation constant), Kd (equilibrium dissociation constant), the invention provides that the antibody has a Kd value of no greater than 5.70 nM; the humanized anti-A beta monoclonal antibody provided by the invention can promote phagocytosis of A beta by macrophages, protect nerve cells from toxicity of A beta and has the function of improving cognitive learning and memory ability of mice in Alzheimer dementia models to a certain extent.

The invention also provides the nucleotide for coding the monoclonal antibody.

The invention provides a nucleotide sequence for encoding the heavy chain of the monoclonal antibody.

The invention provides a nucleotide sequence for encoding the monoclonal antibody light chain.

The invention provides a nucleotide sequence for encoding the heavy chain variable region of the monoclonal antibody.

Wherein, the nucleotide sequence for coding the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO. 25-29 or is a complementary sequence of SEQ ID NO. 25-29.

In some embodiments of the present invention, the nucleotide has a nucleotide sequence obtained by substituting, deleting or adding one or more nucleotides to the nucleotide sequence shown in any one of SEQ ID NOs.25 to 29, and has the same or similar function as the nucleotide sequence shown in any one of SEQ ID NOs.25 to 29.

In some embodiments of the invention, the nucleotide sequence shown in any one of SEQ ID NO 25-29 is obtained by substituting, deleting or adding one or more nucleotides, wherein the nucleotides are 2, 3, 4 or 5.

The invention provides a nucleotide sequence for encoding the variable region of the monoclonal antibody light chain.

Wherein the nucleotide sequence for coding the variable region of the monoclonal antibody light chain is shown as SEQ ID NO 30-34 or is a complementary sequence of SEQ ID NO 30-34.

In some embodiments of the present invention, the nucleotide has a nucleotide sequence obtained by substituting, deleting or adding one or more nucleotides to the nucleotide sequence shown in any one of SEQ ID NOs 30 to 34, and has the same or similar function as the nucleotide sequence shown in any one of SEQ ID NOs 30 to 34.

In some embodiments of the present invention, the nucleotide sequence shown in any one of SEQ ID NO 30-34 is obtained by substituting, deleting or adding one or more nucleotides, wherein the plurality is 2, 3, 4 or 5.

The expression vector provided by the invention comprises nucleotide for coding the anti-Abeta monoclonal antibody.

The invention also provides a host cell transformed or transfected with the expression vector.

The preparation method of the anti-Abeta monoclonal antibody comprises the following steps: culturing the host cell, and inducing the expression of the anti-Abeta monoclonal antibody.

The invention also provides the anti-Abeta monoclonal antibody which is chemically marked or biological marked.

The chemical label is an isotope, an immunotoxin and/or a chemical drug;

the biomarker is a biotin, avidin, or enzyme label.

The enzyme label is preferably horseradish peroxidase or alkaline phosphatase.

The immunotoxin is preferably aflatoxin, diphtheria toxin, pseudomonas aeruginosa exotoxin, ricin, abrin, mistletoe agglutinin, modeccin, PAP, nystatin, gelonin or luffa toxin.

The invention relates to a conjugate prepared by coupling an anti-Abeta monoclonal antibody or a conjugate thereof with a solid medium or a semisolid medium.

The solid medium or the non-solid medium is selected from colloidal gold, polystyrene flat plates or beads.

The invention also provides the use of the monoclonal antibody, the conjugate and/or the conjugate in the preparation of an agent against cognitive impairment, a therapeutic agent for alzheimer's disease, an agent for suppressing the progression of alzheimer's disease, an agent for inhibiting the formation of senile plaques, an agent for suppressing the accumulation of a β, an anti-neurotoxic agent, an agent for inhibiting the formation of a β amyloid fibrils and/or an agent against synaptic toxicity.

The invention also provides the application of the humanized anti-Abeta monoclonal antibody, the conjugate and/or the conjugate in the preparation of medicaments for preventing and treating diseases;

the diseases include amyloidosis, which is a disease and abnormality associated with amyloid protein, including secondary amyloidosis and age-related amyloidosis, including, but not limited to, neurological diseases such as alzheimer's disease.

The invention also provides medicaments comprising the humanized anti-a β monoclonal antibodies, conjugates and/or conjugates thereof.

The present invention also provides a method for the prophylaxis and/or treatment of a disease, comprising administering the agent of the present invention; the diseases and disorders include amyloidosis, which is a disease and disorder associated with amyloid protein, including secondary amyloidosis and age-related amyloidosis, including, but not limited to, neurological diseases such as alzheimer's disease.

The humanized anti-A beta monoclonal antibody provided by the invention can promote phagocytosis of A beta by macrophages, protect nerve cells from toxicity of A beta, has a certain effect of improving cognitive learning and memory capacity of mice in Alzheimer dementia models, and can be used for treating and diagnosing diseases and symptoms related to amyloidosis, such as Alzheimer disease.

The invention relates to application of a humanized anti-A beta monoclonal antibody, a conjugate and/or a conjugate in preparation of a product for detecting A beta expression.

Experiments show that the humanized anti-A beta monoclonal antibody provided by the invention can be combined with an A beta monomer or polymer mixture. Therefore, the humanized anti-A beta monoclonal antibody provided by the invention can be used for detecting A beta monomer or polymer mixture.

The invention also provides a kit comprising the humanized anti-a β monoclonal antibody, conjugates and/or conjugates thereof.

The kit for detecting the A beta monomer or polymer mixture further comprises a coating buffer solution, a washing solution, a sealing solution and/or a developing solution.

The coating buffer is a carbonate buffer.

The washing solution comprises PBS, Tween, sodium chloride, potassium chloride, disodium hydrogen phosphate and dipotassium hydrogen phosphate.

The blocking solution comprises PBS and BSA.

The color development liquid comprises a TMB solution, a substrate buffer solution and a stop solution.

The substrate buffer comprises citric acid and disodium hydrogen phosphate.

The stop solution is aqueous hydrogen peroxide solution.

The kit for detecting the cells with the surface expressing the A beta also comprises PBS, goat anti-mouse IgG Fc and a TITC secondary antibody.

The diagnostic method of a disease, detect the expression of A beta with the kit that the invention provides, judge whether to suffer from the disease according to the expression level of A beta; the diseases and disorders include amyloidosis, a group of diseases and disorders associated with amyloid protein, including secondary amyloidosis and age-related amyloidosis, including, but not limited to, neurological diseases such as alzheimer's disease.

In some embodiments of the present invention, the criterion for determining whether a disease is present or absent according to the expression level of a β is: the detection sensitivity of the kit is less than 20pg/ml for normal people of 600-1000 pg/ml and AD patients of 200-450 pg/ml.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. With regard to the definitions and nomenclature in this field, the expert can refer in particular to Current protocols in Molecular Biology (Ausubel). The abbreviations for amino acid residues are standard 3-letter and/or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.

An "antibody" refers to a protein composed of one or more polypeptides that specifically bind to an antigen. One form of antibody constitutes the basic building block of an antibody. This form is a tetramer, which is composed of two identical pairs of antibody chains, each pair having a light chain and a heavy chain. In each pair of antibody chains, the variable regions of the light and heavy chains are joined together and are responsible for binding to antigen, while the constant regions are responsible for the effector functions of the antibody.

The "variable region" of an antibody heavy or light chain is the N-terminal mature region of the chain. The types of antibodies currently known include kappa and lambda light chains, as well as alpha, gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu heavy chains or other type equivalents thereof. Full-length immunoglobulin "light chains" (about 25kDa or about 214 amino acids) contain a variable region of about 110 amino acids at the NH 2-terminus and a kappa or lambda constant region at the COOH-terminus. The full-length immunoglobulin "heavy chain" (about 50kDa or about 446 amino acids) likewise comprises a variable region (about 116 amino acids), and one of the heavy chain constant regions, e.g., gamma (about 330 amino acids).

"antibody" includes any isotype of antibody or immunoglobulin, or antibody fragments that retain specific binding to an antigen, including but not limited to Fab, Fv, scFv, and Fd fragments, chimeric antibodies, humanized antibodies, single chain antibodies, and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. The antibody may be labeled and detected, for example, by a radioisotope, an enzyme capable of producing a detectable substance, a fluorescent protein, biotin, or the like. The antibodies can also be bound to a solid support, including but not limited to polystyrene plates or beads, and the like.

"humanized antibody" refers to an antibody that comprises CDR regions derived from a non-human antibody, and the remainder of the antibody molecule is derived from one (or more) human antibody. Furthermore, to preserve binding affinity, some residues of the backbone (referred to as FR) segment may be modified.

The term "monoclonal antibody" refers to a preparation of antibody molecules having a single molecular composition. Monoclonal antibody compositions exhibit a single binding specificity and affinity for a particular epitope.

The medicament contains at least one functional component and also comprises a medicinal carrier. Preferably, the pharmaceutically acceptable carrier is water, aqueous buffered solutions, isotonic saline solutions such as PBS (phosphate buffered saline), glucose, mannitol, dextrose, lactose, starch, magnesium stearate, cellulose, magnesium carbonate, 0.3% glycerol, hyaluronic acid, ethanol, or polyalkylene glycols such as polypropylene glycol, triglycerides, and the like. The type of pharmaceutically acceptable carrier used depends inter alia on whether the composition according to the invention is formulated for oral, nasal, intradermal, subcutaneous, intramuscular or intravenous administration. The compositions according to the invention may comprise wetting agents, emulsifiers or buffer substances as additives.

As used herein, "CDR regions" or "CDRs" refer to the hypervariable regions of the heavy and light chains of an immunoglobulin, as defined by Kabat et al (Kabat et al, Sequences of proteins of immunological interest,5th ed., u.s.department of Health and Human Services, NIH,1991, and later versions). There are three heavy chain CDRs and three light chain CDRs. As used herein, the term CDR or CDRs is intended to indicate one of these regions, or several or even all of these regions, which comprise the majority of the amino acid residues responsible for binding by the affinity of the antibody for the antigen or its recognition epitope, as the case may be.

The invention provides an antibody humanization transformation method, which carries out reasonable antibody humanization design by FR transplantation on a reference multi-template to obtain a humanized antibody with the affinity equivalent to that of a murine antibody.

The preparation method of the humanized anti-A beta monoclonal antibody provided by the invention comprises the following steps:

step 1: preparing mouse hybridoma, and obtaining an antibody sequence through 5' RACE;

step 2: humanization of the antibody, sequence alignment on an NCBI tool, completion of humanization modification, and screening of the modified antibody.

Specifically, the method comprises the following steps:

the preparation method of the humanized anti-Abeta monoclonal antibody comprises the following steps: using a mouse antibody 066-7.17.2 as a template, performing PCR amplification to obtain an antibody heavy chain variable region gene VH and a light chain variable region gene VL, translating the genes into amino acid sequences, comparing the amino acid sequences with human antibody sequences in an NCBI database, respectively selecting 5 human antibody sequences with the highest similarity to the variable region VH and VL, using the sequences as a humanized transformation reference template, determining a CDR region of the mouse antibody 066-7.17.2, keeping the CDR region unchanged, transplanting FR regions in the 5 reference templates of the VH and VL respectively to 066-7.17.2 to obtain humanized sequences, and respectively constructing transient expression vectors after codon optimization; transferring the expression vector into 293E cells for expression to obtain a humanized antibody specifically combined with A beta; the humanized A beta antibody is finally obtained by affinity determination, determination of the EC50 value bound with the antigen, activity detection of macrophage phagocytosis A beta and cytotoxic protection detection of the humanized antibody.

The humanized anti-A beta monoclonal antibody provided by the invention can promote phagocytosis of A beta by macrophages, protect nerve cells from toxicity of A beta, has a certain effect of improving cognitive learning and memory capacity of mice of an Alzheimer dementia model, and can be used for treating and diagnosing diseases and symptoms related to amyloidosis, such as Alzheimer disease.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.

FIG. 1 shows SDS-PAGE and WB detection of A β monomers and polymer mixtures; lane M: protein molecular weight markers; lane 1: a β monomer; lane 2: a β polymer blend; fig. 1 (a): SDS-PAGE detection of A beta monomer and polymer mixture; FIG. 1 (B): WB detection of Abeta monomer and polymer mixture;

FIG. 2 shows SDS-PAGE electrophoresis to detect purified positive antibodies; lane M: protein molecular weight markers; lane 1: 066-P01 non-reducing electrophoresis; lane 2: 066-P01 reduction electrophoresis; lane 3: 066-P02 non-reducing electrophoresis; lane 4: 066-P02 reduction electrophoresis; fig. 2 (a): SDS-PAGE electrophoresis detection result of the purified positive antibody 066-P01; fig. 2 (B): SDS-PAGE electrophoresis detection result of the purified positive antibody 066-P02;

FIG. 3 shows that anti-A.beta.monoclonal antibodies inhibit A.beta.polymerization assays; the abscissa is different sample adding groups, the ordinate is relative fluorescence intensity, and the anti-Abeta monoclonal antibodies 066-4.22.1, 066-4.26.14, 066-5.4.1 and the like can inhibit Abeta polymerization; wherein, FIG. 3(A) shows the result of detecting the inhibition of Abeta polymerization by IgG, 066-P01, 066-5.4.1, 066-6.1.1, 066-6.1.3, 066-6.2.1 and 066-6.7.2 anti-Abeta monoclonal antibodies; FIG. 3(B) shows the detection results of the inhibition of Abeta polymerization by the anti-Abeta monoclonal antibodies of PBS, IgG, 066-4.21.13, 066-4.26.14, 066-4.6.8, 066-4.22.1, 066-4.18.2 and 066-P01 in the sample-loading group;

FIG. 4 shows the measurement of macrophage phagocytosis of A.beta.by anti-A.beta.monoclonal antibody; the abscissa is different sample adding groups, the ordinate is fluorescence intensity, and the 066-5.4.1 and 066-7.17.2 anti-Abeta monoclonal antibodies have the activity of promoting macrophages to phagocytose Abeta;

FIG. 5 shows the anti-A β monoclonal antibody cytotoxicity protection activity assay; the abscissa is different sample adding groups, the ordinate is relative values of LDH release, and the 066-4.26.14, 066-5.4.1, 066-6.1.1, 066-6.1.3, 066-6.2.1, 066-6.7.2 and 066-7.17.2 antibodies have cytotoxic protection effects which are equivalent to 066-P02; wherein, FIG. 5(A) shows the detection results of cytotoxic protection activity of anti-Abeta monoclonal antibodies of Vehicle, IgG, 066-4.21.13, 066-4.17.28, 066-4.6.8, 066-4.22.1, 066-4.26.14, 066-4.18.2 and 066-P02 respectively; FIG. 5(B) shows the result of detecting the cytotoxic activity of anti-Abeta monoclonal antibodies of Vehicle, IgG, 066-6.2.1, 066-7.17.2, 066-5.4.1, 066-6.1.1, 066-6.1.3, 066-6.7.2, and 066-P02 for the loading groups, respectively;

FIG. 6 shows the results of the Morris water maze test; the abscissa is the time after treatment (

days

1, 2, 3, 4, 5), and the ordinate is the time to find the hidden platform under the water (unit: Sec);

FIG. 7 shows total RNA agarose gel electrophoresis detection; lane M: DL2000 molecular weight markers; lane 1: 066-7.17.2 Total RNA electrophoresis band;

FIG. 8 shows agarose gel electrophoresis detection of heavy chain variable regions and light chain variable regions of candidate antibodies amplified by PCR; lane M: DL2000 molecular weight markers; lane 1: 066-7.17.2 heavy chain variable region PCR product electrophoresis band; lane 2: 066-7.17.2 light chain variable region electrophoretic band; among them, FIG. 8(A) shows the results of PCR for the heavy chain variable region from 066-7.17.2; FIG. 8(B) shows the results of PCR for the light chain variable region from 066-7.17.2;

FIG. 9 shows SDS-PAGE electrophoresis detection of purified murine human chimeric antibody 066-7.17.2-chb; lane M: protein molecular weight markers; lane 1: non-reducing electrophoresis of a mouse human chimeric antibody 066-7.17.2-chb; lane 2: reducing electrophoresis of a mouse human chimeric antibody 066-7.17.2-chb;

FIG. 10 shows SDS-PAGE electrophoresis detection of purified parent humanized candidate antibodies; lane M: protein molecular weight markers; in fig. 10 (a): lanes 1-6 are non-reducing electrophoresis with humanized antibodies 066-7.17.2H5L5, 066-7.17.2H4L5, 066-7.17.2H3L5, 066-7.17.2H2L5, 066-7.17.2H2L3, 066-7.17.2H1L5, respectively; in fig. 10 (B): lanes 1-6 are reduced electrophoresis with humanized antibodies 066-7.17.2H5L5, 066-7.17.2H4L5, 066-7.17.2H3L5, 066-7.17.2H2L5, 066-7.17.2H2L3, and 066-7.17.2H1L5, respectively;

FIG. 11 shows the assay of macrophage phagocytosis of A.beta.by humanized A.beta.antibody; the abscissa is different sample adding groups, the ordinate is fluorescence intensity, and the 066-7.17.2 humanized candidate antibodies have the activity of promoting phagocytosis of Abeta by macrophages;

FIG. 12 shows humanized A β antibody cytotoxic protection activity assay; the abscissa is different loading groups, the ordinate is a relative value of LDH release, and the 066-7.17.2 humanized candidate antibodies all have cytotoxic protection effects which are equivalent to 066-P02, wherein 066-7.17.2H3L5 is optimal.

Detailed Description

The invention discloses a humanized anti-Abeta monoclonal antibody and application thereof, and a person skilled in the art can realize the humanized anti-Abeta monoclonal antibody by properly improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.

The humanized anti-Abeta monoclonal antibody and the raw materials and reagents used in the application thereof can be purchased from the market.

The invention is further illustrated by the following examples:

example 1 preparation of Abeta antigen and Positive control antibody

Preparation of Abeta monomer and Polymer mixtures

Aβ_1-42、Aβ_1-16、Aβ_14-29The polypeptide was synthesized by gill biochemical (shanghai) ltd. Abeta (beta)_1-42The polypeptide amino acid sequence is as follows: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID:35), A.beta._1-16The polypeptide amino acid sequence is as follows: DAEFRHDSGYEVHHQK (SEQ ID:36), A.beta._14-29The polypeptide amino acid sequence is as follows: HQKLVFFAEDVGSNKGA (SEQ ID: 37))。

Aβ_1-42Monomer (abbreviated as Abeta monomer) preparation method: to 1mg of Abeta_1-42Adding 1ml of Hexafluoroisopropanol (HFIP) into the polypeptide dry powder, performing vortex oscillation for 1min, and performing ultrasonic treatment in water bath for 1-5min until the polypeptide dry powder is completely dissolved; placing the mixture in a shaking incubator at 37 ℃ and 200rpm for shaking for 1.5 h; volatilizing hexafluoroisopropanol by using a vacuum rotary dryer; to dry A beta_1-42192. mu.l of anhydrous dimethyl sulfoxide (DMSO) was added to the polypeptide to dissolve the polypeptide, and 27. mu.l of 20 XPBS solution, 54. mu.l of 2% SDS, 267. mu.l of ddH were added₂O, mixing, subpackaging in small amount, and storing in-80 deg.C refrigerator to obtain Abeta_1-42A monomer; by SDS-PAGE and WB (using the specifically recognized A.beta._1-42A positive antibody 066-P02 from the polymer was subjected to hybridization assay) (see fig. 1).

Aβ_1-42Polymer mixture (abbreviated as Α β polymer mixture) preparation method: to 1mg of Abeta_1-42Adding 1ml of Hexafluoroisopropanol (HFIP) into the polypeptide dry powder, performing vortex oscillation for 1min, and performing ultrasonic treatment in water bath for 1-5min until the polypeptide dry powder is completely dissolved; placing the mixture in a shaking incubator at 37 ℃ and 200rpm for shaking for 1.5 h; volatilizing hexafluoroisopropanol by using a vacuum rotary dryer; to dry A beta_1-42192. mu.l DMSO was added to the polypeptide to dissolve the polypeptide, and 27. mu.l 20 XPBS solution, 54. mu.l 2% SDS, 267. mu.l ddH were added₂O, mixing evenly, and placing in a water bath at 37 ℃ for 18-24 h; to this was added 1.62ml of ddH₂O, mixing evenly, and placing in a water bath at 37 ℃ for 18-24 h; replacing the buffer solution with 10KDa ultrafiltration concentration tube to PBS, subpackaging in small amount, and storing in-80 deg.C refrigerator to obtain Abeta_1-42A polymer mixture; by SDS-PAGE and WB (using the specifically recognized A.beta._1-42A positive antibody 066-P02 from the polymer was subjected to hybridization assay) (see fig. 1).

2. Positive control antibody expression vector construction

pGS003-hIgG1CH and pGS003-hIgKCL are respectively selected as expression vectors for constructing heavy chains and light chains of anti-human Abeta positive antibodies (066-P01: Solanezumab, Eli lily, 066-P02: Aducanum ab, Biogen), after codon optimization of amino acid sequences of variable regions of the positive antibodies, genes of the VH and VL of the positive antibodies are respectively cloned to pGS003-hIgG1CH and pGS003-hIgKCL by using an enzyme digestion method to obtain the transient expression vectors of the heavy chains and the light chains of the positive antibodies, namely pGS003-066-P02VH-hIgG1CH and pGS-066-P02 VL-hIgKCL. The heavy chain variable region amino acid sequence of the 066-P01 positive antibody is as follows (SEQ ID: 38):

EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVG NSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS

the amino acid sequence of the light chain variable region of the 066-P01 positive antibody is as follows (SEQ ID: 39):

DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK

the heavy chain variable region amino acid sequence of the 066-P02 positive antibody is as follows (SEQ ID: 40):

QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFD GTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYM DVWGKGTTVTVSS

the amino acid sequence of the light chain variable region of the 066-P02 positive antibody is as follows (SEQ ID: 41):

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK

3. instantaneous expression

pGS003-066-P01VH-hIgG1CH and pGS003-066-P01 VL-hIgKCL;

pGS003-066-P02VH-hIgG1CH and pGS003-066-P02VL-hIgKCL were transiently expressed.

Using FreeStyle^TM293E cells in Freestyle medium for transient expression. 24 hours before transfection, 0.5X 10 inoculum was inoculated in 125ml Erlenmeyer flasks⁶30ml of 293E cells per ml, 5% CO at 37 ℃₂Shaking the culture in an incubator at 130 rpm. During transfection, 60 microliters of 293E Fectin are added into 1ml of Opti-MEM, and after the mixture is fully mixed, the mixture is incubated for 5 minutes at room temperature; meanwhile, the amount of the total plasmid DNA of the recombinant vector was 30. mu.g, dissolved in 1ml of Opti-MEM. Then the plasmid DNA and 293E Fectin were mixed well, the total volume was 2ml, incubated at room temperature for 15 minutes, then the mixture was added to the cell culture wells in its entirety, mixed well, 5% CO at 37 ℃₂Shaking at 130rpm in incubator for 7 days. Centrifuging the culture solution at high speed, collecting the supernatantAnd (5) vacuumizing and filtering the microporous filter membrane.

4. Protein purification

Purifying with Protein A column (Protein purification liquid chromatography system/AKTA Purifier 10, GE) and nickel column to obtain purified positive antibodies 066-P01 and 066-P02. As shown in fig. 2.

EXAMPLE 2 anti-A.beta.monoclonal hybridoma preparation

1. Immunization of BALB/c mice

Mixing A beta_1-42The polypeptide antigen and Freund's complete adjuvant are mixed by vortex according to dosage, and BALB/c female mice of 6 weeks old are immunized for the first time after complete emulsification. Each mouse was injected intraperitoneally with 200. mu.g of antigen, and 3 groups of mice were immunized in total, with 5 mice each. Two weeks after the first immunization, the mice were subjected to a second intraperitoneal immunization using Freund's incomplete adjuvant, and the immunization antigen doses were the same for the first immunization. Mice were immunized intraperitoneally twice a month thereafter, with the same adjuvant and antigen doses as for the second immunization.

And (3) after the first immunization, performing orbital small-amount blood collection on the mice every six weeks, performing serum titer detection, detecting the serum titer reaches 1:200000 or more by an indirect ELISA method, and performing boosting immunization on the mice for fusion.

2. Preparation of myeloma cells for fusion

Myeloma cells P3X63Ag8.653 for fusion were recovered three weeks in advance and cultured for two weeks in DMEM medium containing 1X 8-azaguanine and 10% fetal bovine serum, and cultured in DMEM medium containing 10% fetal bovine serum for one week of fusion, maintaining the density of P3X63Ag8.653 at 70% -80% until the day of fusion.

3. Cell fusion and HA screening

Acquisition and preparation of splenocytes: 2 mice after boosting were taken, sacrificed after immune serum was collected and soaked in 75% alcohol for 2-3 minutes. The skin and peritoneum were cut from the ventral side of the immunized mice, exposing the spleen. Removing peripheral tissues by using a tip to obtain a spleen, grinding by using a grinding rod, and filtering by using a cell screen to prepare a single cell suspension. Centrifuging and then discarding the supernatant,

cell fusion pretreatment: P3X63Ag8.653 in the culture flask was collected, centrifuged at 1000rpm/5min, the supernatant was discarded, and viable myeloma cells were counted after resuspension. Centrifuging the spleen cell suspension, removing supernatant, adding ACK lysate, incubating, centrifuging, removing red blood cells, resuspending with DMED, and counting spleen viable cells.

Cell fusion: according to the ratio of splenocytes: mixing cells at a ratio of P3X63Ag8.653 to 1:2, centrifuging at 2000rpm/5min, discarding supernatant, shaking off cell pellet, and mixing at 400 μ l/1 × 10⁸Adding 1mg/ml Pronase into splenocytes, incubating for 15 seconds, adding 10ml fetal calf serum to stop reaction, adding electrotransfer solution (ECF) to 50ml, centrifuging at 2500rpm for 5 minutes, removing supernatant, resuspending ECF, counting viable cells, adjusting the density of splenocytes to 2 × 10⁶And/ml. Adding the cell suspension with the adjusted density into an electric fusion tank, operating an electric transfer instrument to perform cell fusion, transferring the cell suspension from the fusion tank into 1/2HA culture medium after the fusion is finished, and performing cell plating after standing for 3 hours.

HA medium screening: AT selection medium containing 1/2HA, 1 × QINGNIN-streptomycin, 20% fetal bovine serum and 80% DMEM medium was prepared. The murine hybridoma cells were resuspended in the 1/2HA screening medium and mixed well. At a volume of 200. mu.l/well, 1X 10⁶Spleen cells/plate, add cell suspension to 96-well cell culture plate, and culture in 37 ℃ cell culture box. After 1 week of culture, the cells were first changed with 1/2HA medium and placed in a 37 ℃ cell culture box for further culture, and after 3 days of culture, the cells were changed with 1/2HA medium for the second time.

4. Screening of Positive cell lines

2 weeks after the fusion, cell supernatants were taken for ELISA assay to detect cell supernatants and human Abeta_1-42Screening out cells with positive ELISA result, and retesting the ELISA result for the second time. And taking the cell supernatant with positive retest result for subcloning and expanding culture.

5. Expanding culture

Transferring the cell strain with positive ELISA detection into 24-hole from 96-hole for culture, and transferring into 25cm after full growth²Culturing in a culture flask.

6. Subcloning by limiting dilution method

Positive of mixing by blowing and beatingCell lines and small amounts were aspirated for viable cell counting. About 200 cells were pipetted into 80ml of complete medium and mixed well and plated in 4 plates. About 400 additional cells were pipetted into 80ml of complete medium and mixed well and plated in 4 plates. About 1000 additional cells were pipetted into 20ml of complete medium and mixed well and plated in 1 block. In total, 9 blocks were plated at 3 different cell densities, 0.5, 1, and 10 cells/well, respectively. Placing 96-well plate at 37 deg.C and 5% CO₂Culturing in an incubator.

7. Clone detection and expanded culture

Taking supernatant of monoclonal cell hole to carry out ELISA detection, and respectively detecting cell clone antibody and Abeta_1-42Full length, Abeta_1-42Binding of the N-terminal and intermediate peptide fragments.

Coating: streptavidin was diluted to 1. mu.g/ml with CBS (pH 9.6) and added to 96 wells of an microplate, 50. mu.l per well, and incubated overnight at 2-8 ℃.

And (3) sealing: after washing the plates once with PBST, they were blocked with 1% BSA, 200. mu.l per well and incubated for 1 hour at room temperature.

Antigen: after washing the plate three times with PBST, biotinylated Abeta was taken separately_1-42、Aβ_1-16、Aβ_14-29The polypeptides, diluted to 1. mu.g/ml with PBS (pH 7.2), were added to 96 wells of an ELISA plate at 50. mu.l per well and incubated at room temperature for 1 hour.

Adding a primary antibody: after washing the plate three times with PBST, the murine candidate antibody was added at 50. mu.l/well and incubated at room temperature for 2 hours.

Adding a secondary antibody: after washing the plate three times with PBST, anti-mouse IgG Fc-HRP antibody, 1:5000 dilution, 50. mu.l/well was added and incubated at room temperature for 1 hour.

Color development: after washing the plate six times with PBST, 50. mu.l of TMB developing solution was added to each well, and the plate was developed in the dark at room temperature for 10 minutes.

And (4) terminating: stop solution was added directly to stop the reaction, 50. mu.l per well.

And (3) detection: immediately placing the ELISA plate into an ELISA reader after the reaction is terminated, measuring the OD value at 450nm, and storing the original data.

Data processing: the raw data were input into the software SoftMaxPro 6.2.1 for data processing. Specific data are shown in the table1. The results showed that 12 murine candidate antibodies contained three different epitopes, N-terminal (A β) respectively_1-16) Terminal C (Abeta)_30-42) Intermediate (Abeta.) of_14-29) A peptide fragment. Among them, 066-7.17.2 epitope was grouped as Abeta_1-42An N-terminal peptide fragment.

TABLE 1 grouping test results of mouse-derived candidate antibody epitopes

Name of antibody	Aβ_1-42Full length	Aβ_1-16(N-terminal peptide fragment)	Aβ_14-29(intermediate peptide fragment)	Epitope
					066-4.6.8	1.2944	0.0561	0.5115	Intermediate peptide fragment
066-4.17.28	1.4540	0.0690	1.1238	Intermediate peptide fragment
					066-4.18.2	1.0925	1.2210	0.0848	N-terminal peptide fragment
066-4.21.13	1.3647	0.056	1.1457	Intermediate peptide fragment
					066-4.22.1	1.2517	0.0773	1.0401	Intermediate peptide fragment
066-4.26.14	1.9312	0.0602	0.0674	C-terminal peptide fragment
					066-5.4.1	1.2483	0.0540	1.1566	Intermediate peptide fragment
066-6.1.1	1.3752	0.1001	0.1180	C-terminal peptide fragment
					066-6.1.3	1.3665	0.0618	0.0803	C-terminal peptide fragment
066-6.2.1	1.3085	0.0975	0.1003	C-terminal peptide fragment
					066-6.7.2	1.4707	1.6608	0.3058	N-terminal peptide fragment
066-7.17.2	1.0833	0.9197	0.0612	N-terminal peptide fragment

8. Identification of subclasses

Coating goat anti-mouse IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgM and IgGA, 50ng/100 mu l/hole, keeping overnight at 4 ℃, blocking BSA at room temperature, adding cell supernatant to be detected, incubating for 2 hours at room temperature, adding enzyme-labeled secondary goat anti-mouse IgG, kappa and lambda, developing, stopping, reading at 450nm, judging the subclass of the cell strain to be IgG1, kappa or IgG2a, kappa or IgG2b, and the result is shown in Table 2. Wherein, the heavy chain constant region of 066-7.17.2 is mouse IgG1, and the light chain constant region is the constant region of mouse kappa chain.

TABLE 2 results of the detection of murine candidate subtypes

Name of antibody	Subtype of cell
		066-4.6.8	IgG1，Kappa
066-4.17.28	IgG1，Kappa
		066-4.18.2	IgG2b，Kappa
066-4.21.13	IgG1，Kappa
		066-4.22.1	IgG1，Kappa
066-4.26.14	IgG2a，Kappa
		066-5.4.1	IgG1，Kappa
066-6.1.1	IgG2a，Kappa
		066-6.1.3	IgG2a，Kappa
066-6.2.1	IgG2a，Kappa
		066-6.7.2	IgG2a，Kappa
066-7.17.2	IgG1，Kappa

9. Cell cryopreservation

Preparing a frozen stock solution: 90% fetal bovine serum, 10% DMSO.

Resuspending the cells in the flask, counting the cells, centrifuging at 1000rpm/min for 5min, discarding the supernatant, pipetting with 10% DMSO in fetal calf serum, and resuspending at 5X 10⁶Cells/tubes were cryopreserved in a cryopreservation box at-80 ℃ overnight, and transferred into liquid nitrogen the next day.

10. Monoclonal hybridoma gene preservation

Collecting positive monoclonal cell strain, adding TRizol to crack cell and extract RNA, reverse transcription to cDNA, and storing at-80 deg.c.

11. Antibody preparation by in vitro culture method

Reviving the prepared hybridoma cell strain by reviving a DMEM medium containing 10% fetal calf serum and 1% streptomycin, culturing by using a small bottle, carrying out subculture expansion after the confluence degree of the cells is about 90%, expanding the cells until the cell culture supernatant is about 200ml, collecting the supernatant, carrying out centrifugal filtration, and purifying.

Example 3 anti-Abeta monoclonal antibody inhibits Abeta polymerization assay

The A beta dry powder was dissolved with 8.2% DMSO/DPBS solution (DMSO: sigma; DPBS: Hyclone) to 1mg/ml, the DPBS diluted the A beta solution to 33. mu.g/ml, the anti-A beta monoclonal antibodies 066-4.6.8, 066-4.18.2, 066-4.22.1, 066-4.26.14, 066-5.4.1, 066-6.1.1, 066-6.1.3, 066-6.2.1, 066-6.7.2 to 450. mu.g/ml (IC100), and the ThT (sigma) diluted with ultrapure water to 20. mu.M. 50 μ l of the antibody dilution was added to a 96-well blackboard (corning), and then 50 μ l A β dilution was added thereto, and finally 100 μ l ThT was added thereto, and incubated at room temperature in the dark for 24 hours, and the fluorescence intensity was measured with a multifunctional microplate reader (Ex/Em ═ 440/485). The abscissa represents different sample application groups, and the ordinate represents relative fluorescence intensity, and the results are shown in FIG. 3. In FIG. 3(A), when the relative fluorescence intensity of the IgG group was 1.0, the relative fluorescence intensity of the anti-A β monoclonal antibody 066-5.4.1 group was 0.59; in FIG. 3(B), when the relative fluorescence intensity of the PBS group was 1.0, the relative fluorescence intensity of the anti-A β monoclonal antibody 066-4.22.1 group was 0.44, and the relative fluorescence intensity of the anti-A β monoclonal antibody 066-4.26.14 group was 0.46; it can be seen that anti-A beta monoclonal antibodies 066-4.22.1, 066-4.26.14, 066-5.4.1, etc. all inhibit A beta polymerization.

Example 4 detection of macrophage phagocytosis of A.beta.Activity by anti-A.beta.monoclonal antibodies

Mouse primary abdominal cavity macrophage with good adherence for 3 days, digesting with 0.25% trypsin, counting, and adjusting cell density to 2 × 10 with DMEM culture medium (Gibco) containing 10% serum fetal bovine serum⁵Seed 96-well cell culture plate in 100. mu.l/well; a beta-resistant monoclonal antibodies of 20 mu g/ml are used as working solutions, A beta is diluted to 240 mu g/ml, and ThT sigma is diluted to 20 mu M in ultrapure water, wherein the working solutions are obtained by diluting 066-4.6.8, 066-4.17.28, 066-4.18.2, 066-4.21.13, 066-4.22.1, 066-4.26.14, 066-5.4.1, 066-6.1, 066-6.1.3, 066-6.2.1, 066-6.7.2 and 066-7.17.2 in DMEM culture medium with 1% fetal bovine serum. Discarding the culture medium in the culture plate, adding 50 μ l of antibody diluent, adding 50 μ l A β diluent, and setting multiple wells; 37 ℃ and 5% CO₂Culturing for 6 hours in an incubator; 50. mu.l of the supernatant was put into a 96-well blackboard, and 50. mu.l of ThT was added thereto, and the fluorescence intensity was measured by a multifunctional microplate reader (Ex/Em. 440/485). The abscissa represents the different sample addition groups, and the ordinate represents the fluorescence intensity, and the results are shown in FIG. 4. Wherein, the fluorescence intensity of the group of the anti-A beta monoclonal antibody 066-5.4.1 is 650000, and the fluorescence intensity of the group of the anti-A beta monoclonal antibody 066-7.17.2 is 600000. It can be seen that the anti-A beta monoclonal antibodies 066-5.4.1 and 066-7.17.2 have the activity of promoting macrophage to phagocytize A beta.

Example 5 anti-Abeta monoclonal antibody cytotoxicity protective Activity assay

Logarithmic growth phase SHSY5Y cells, digested with 0.25% trypsin and countedThe cell density was adjusted to 3X 10 by using EMEM culture medium (ATCC) containing 10% fetal bovine serum⁴Seed 96-well cell culture plate in 100. mu.l/well; the A beta monoclonal antibodies of 1 percent fetal calf serum are diluted to 200 mu g/ml (IC100) by EMEM culture medium 066-4.6.8, 066-4.17.28, 066-4.18.2, 066-4.21.13, 066-4.22.1, 066-4.26.14, 066-5.4.1, 066-6.1.3, 066-6.2.1, 066-6.7.2 and 066-7.17.2, and are used as working solution, and the A beta is diluted to 240 mu g/ml. Discarding the culture medium in the culture plate, adding 50 μ l of antibody diluent, adding 50 μ l A β diluent, and setting multiple wells; 5% CO at 37 ℃₂Culturing in an incubator for 48 hours; adding 50 μ l of supernatant into a new 96-well plate, adding 50 μ l of LDH assay buffer, keeping out of the sun at room temperature for 30min, adding 50 μ l of stop solution, and detecting the absorbance value by a multifunctional enzyme-linked immunosorbent assay. The abscissa is the different loading groups and the ordinate is the relative value of LDH release, and the results are shown in FIG. 5. Wherein, when the relative value of LDH release of the Vehicle group is 1.0, the relative fluorescence intensity of the anti-A beta monoclonal antibody 066-4.26.14 group is 1.2, the relative value of LDH release of the anti-A beta monoclonal antibody 066-5.4.1 group is 1.37, the relative value of LDH release of the anti-A beta monoclonal antibody 066-6.1.1 group is 1.43, the relative value of LDH release of the anti-A beta monoclonal antibody 066-6.1.3 group is 1.35, the relative value of LDH release of the anti-A beta monoclonal antibody 066-6.2.1 group is 1.34, the relative value of LDH release of the anti-A beta monoclonal antibody 066-6.7.2 group is 1.44, and the relative values of LDH release of the positive control antibody 066-P02 group are 1.26(A) and 1.53 (B). It can be seen that the 066-4.26.14, 066-5.4.1, 066-6.1.1, 066-6.1.3, 066-6.2.1, 066-6.7.2 and 066-7.17.2 antibodies all have cytotoxic protection effects, and the protection effects are equivalent to those of 066-P02.

Example 6Morris Water maze experiment

1. The experimental method and the steps are as follows:

experimental animals 3 × Tg mice were purchased from Experimental animals technical Co., Ltd, Kyoto Jilin university medical college, Peking. The grouping situation is as follows:

according to different injection medicines, the injection medicines are divided into an antibody 066-4.26.14 treatment group, an antibody 066-5.4.1 treatment group, an antibody 066-7.17.2 treatment group, a 3 XTg blank control group, a wild type PBS injection group and a positive antibody 066-P02 control group, wherein each group contains 8 antibodies.

Reference (Nabeshima, 2007) was made to the method of intraperitoneal injection of 6-month-old male 3 × Tg mice (500 g/mouse) once a week for 10 weeks into 6-month-old male 3 × Tg mice (mab 066-4.26.14, 066-5.4.1, 066-7.17.2), and after 8 weeks of injection, Morris water maze assay was performed.

Morris water maze detection step:

(1) a specially-made water maze is designed, and mainly comprises a cylindrical pool and a platform with a movable position. The height of the water pool is 45cm, the diameter of the water pool is 100cm, the diameter of the platform is 9cm, the height of the platform is 15-40cm, and the water pool is connected with a computer through a digital camera.

(2) The method comprises the steps of injecting clear water into a water pool in advance, wherein the wall and the bottom of the water pool are black, adding white pigment for food into the water of the water pool, so that a platform below the water surface cannot be seen by a mouse, the water depth is 30cm, and the water surface is 1cm higher than the platform.

(3) The water temperature was controlled at 19 + -1 deg.C and the water entry point was marked in the quadrant outside the quadrant of the platform on the basin. And different-shaped markers are stuck on the corresponding side walls of each quadrant. The platform position was kept constant during the experiment.

(4) Each experiment is carried out in a sound-proof room, and the positions of objects in a laboratory such as a water pool, a light source, a mouse cage and the like are kept unchanged.

(5) Training was started on day 3 after week 8 dosing, and the experiment was continued for a total of 5 days (water maze-Hidden platform test), with 4 measurements per day. When the mouse is put into water, the face of the mouse faces the wall surface of the pool, and the mouse is gently put into the water. The 5 training (experiments) per day were performed randomly in the area outside the set-up platform quadrant, with the first two times of the first two days of the experiment as exercises. The platform was found within 60 seconds by the mouse and left on the platform for 15 seconds, and the platform was not found within 60 seconds by the mouse (latency was recorded as 60 seconds), and then the experimenter led it to the platform and left on the platform for 15 seconds. The average of four incubation periods of the mice was taken as the performance of the mice on the day.

2. Experimental results (see fig. 6):

on day 2 of the Hidden platform test, the time for all antibody administration groups to find the Hidden platform under the water surface (escape latency) was significantly shortened in comparison with the 3 × Tg blank group, which was statistically significant. On day 3, the time required for the anti-A beta monoclonal antibody 066-7.17.2 group to escape from the latency was 18s, the time required for the anti-A beta monoclonal antibody 066-4.26.14 group to escape from the latency was 27 s, the time required for the anti-A beta monoclonal antibody 066-5.4.1 group to escape from the latency was 30s, the time required for the blank control group to escape from the latency was 39s, and the escape latencies of the 066-7.17.2 and 066-4.26.14 drug-administered group control 3 × Tg blank group were significantly shortened, which had statistical significance. Therefore, the anti-Abeta monoclonal antibodies 066-7.17.2 and 066-4.26.14 have certain functions of improving the cognitive learning and memory ability of the mouse model with the Alzheimer dementia.

EXAMPLE 7 monoclonal antibody Gene sequencing and chimeric antibody preparation

1. Monoclonal antibody gene sequencing

After immunization, fusion and monoclonality, a 066-7.17.2 monoclonal antibody cell strain is selected based on the experimental results of binding epitope, macrophage phagocytosis Abeta activity detection, cytotoxic protection activity detection, Morris water maze and the like to extract total RNA, and is reversely transcribed into cDNA, and then the heavy chain variable region and the light chain variable region of the antibody are amplified by PCR by taking the cDNA as a template.

Total RNA extraction of the 066-7.17.2 monoclonal antibody cell line was performed using the TRIZOLREAgent kit (15596-026) from Invitrogen, as described in the manual, and the results are shown in FIG. 7.

Then, 5 ' RACE FULL kit (D315) from Takara was used, the total RNA was used as a template, random primers in the kit were reverse-transcribed to first strand cDNA, then heavy chain primers mIgGR (5 ' -CTCAGGGAARTARCCYTTGAC-3 ', SEQ ID NO:42) designed as a constant region and linker primers in the kit were PCR-amplified, and light chain primers mIgKR (5'-TCACTGCCATCAATCTTCCAC-3', SEQ ID NO:43) designed as a constant region and linker primers in the kit were PCR-amplified, and the results are shown in FIG. 8.

PCR fragments recovered by an agarose gel recovery kit are subjected to TA cloning, then single clones are selected for PCR identification, identification primers are M13F (5'-TGTAAAACGACGGCCAGT-3', SEQ ID NO:44) and M13R (5'-CAGGAAACAGCTATGACC-3', SEQ ID NO:45), and a part of samples selected from correct strains are identified and sent to Invitrogen for sequencing. Finally, it was determined that the nucleotide sequence of the heavy chain variable region was SEQ ID NO 46, the nucleotide sequence of the light chain variable region was SEQ ID NO 47, the amino acid sequence of the heavy chain variable region was SEQ ID NO 48, and the amino acid sequence of the light chain variable region was SEQ ID NO 49, as shown in Table 3.

TABLE 3, 066-7.17.2 antibody heavy chain variable region and light chain variable region specific sequences

The nucleotide sequence of the heavy chain variable region of the 066-7.17.2 antibody is as follows (SEQ ID NO: 46):

GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCT GAAGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGCACTGGG TGAGGCAGGCCCCCGAGAAGGGCCTGGAGTGGGTGGCCATGATCTGGTACGACGGC ACCAAGAAGTACTACAGCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACA ACGCCAAGAACACCCTGTTCCTGCAGATGACCAGCCTGAGGAGCGAGGACACCGCC ATGTACTACTGCGCCAGGGACAGGGGCATCGGCACCAGGCACGGCCCCTACTTCAT GGACGTGTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC

the nucleotide sequence of the light chain variable region of the 066-7.17.2 antibody is as follows (SEQ ID NO: 47):

GACATCCAGATGAACCAGAGCCCCAGCAGCCTGAGCGCCAGCCTGGGCGACAC CATCACCATCACCTGCCACGCCAGGCACAACGTGAGGAGCTACCTGAACTGGTACC AGCAGAAGCCCGGCAACATCCCCAAGCTGCTGATCTACGCCGCCAGCAGCCAGCAG AGGGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGGCTTCACCCTGAC CATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCTGCAGAGCTTCGG CACCCCCCTGACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG

the amino acid sequence of the heavy chain variable region of the 066-7.17.2 antibody is as follows (SEQ ID NO: 48):

EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYGMHWVRQAPEKGLEWVAMIWYD GTKKYYSDSVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARDRGIGTRHGPYFMD VWGQGTSVTVSS

the amino acid sequence of the light chain variable region of the 066-7.17.2 antibody is as follows (SEQ ID NO: 49):

DIQMNQSPSSLSASLGDTITITCHARHNVRSYLNWYQQKPGNIPKLLIYAASSQQRG VPSRFSGSGSGTGFTLTISSLQPEDIATYYCLQSFGTPLTFGGGTKLEIK

2.066-7.17.2 mouse and human chimeric antibody expression vector construction

pGS003-hIgG1CH and pGS003-hIgKCL were selected as expression vectors for constructing heavy and light chains of anti-human Abeta murine chimeric antibodies, respectively. After PCR amplification is carried out by taking the synthesized 066-7.17.2 murine sequence as a template, the VH and VL murine antibody genes are respectively cloned to pGS003-hIgG1CH and pGS003-hIgKCL by using an enzyme digestion connection method to obtain the heavy chain and light chain transient expression vectors pGS003-066-7.17.2-chAb-hIgG1CH and pGS003-066-7.17.2-chAb-hIgKCL of the mouse human chimeric antibody.

066-7.17.2 murine human chimeric antibody heavy chain amino acid sequence is as follows (SEQ ID NO: 50):

EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYGMHWVRQAPEKGLEWVAMIWYDGTKKYYSDSVKGRF TISRDNAKNTLFLQMTSLRSEDTAMYYCARDRGIGTRHGPYFMDVWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

066-7.17.2 murine human chimeric antibody light chain amino acid sequence is as follows (SEQ ID NO: 51):

DIQMNQSPSSLSASLGDTITITCHARHNVRSYLNWYQQKPGNIPKLLIYAASSQQRGVPSRFSGSGSG TGFTLTISSLQPEDIATYYCLQSFGTPLTFGGGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

3. instantaneous expression

pGS003-066-7.17.2-chAbVH-hIgG4CH and pGS003-066-7.17.2-chAbVL-hIgKCL were transiently expressed.

Using FreeStyle^TM293E cells in Freestyle medium for transient expression. 24 hours before transfection, 0.5X 10 inoculum was inoculated in 125ml Erlenmeyer flasks⁶30ml of 293E cells per ml, 5% CO at 37 ℃₂Shaking the culture in an incubator at 130 rpm. During transfection, 60 microliters of 293E Fectin are added into 1ml of Opti-MEM, and after the mixture is fully mixed, the mixture is incubated for 5 minutes at room temperature; at the same time, the total plasmid DNA amount of the recombinant vector is 30 mug, and is dissolved in 1ml of OIn pti-MEM. Then the plasmid DNA and 293E Fectin were mixed well, the total volume was 2ml, incubated at room temperature for 15 minutes, then the mixture was added to the cell culture wells in its entirety, mixed well, 5% CO at 37 ℃₂Shaking at 130rpm in incubator for 7 days. Centrifuging the culture solution at high speed, collecting supernatant, and vacuum filtering with microporous membrane.

4. Protein purification

The purified mouse-human chimeric antibody 066-7.17.2-chb was obtained by purification using Protein A column (Protein purification liquid chromatography system/AKTA Purifier 10, GE) and nickel column according to the manufacturer's protocol, as shown in FIG. 9.

Example 8 antibody humanization

Selecting a murine antibody 066-7.17.2 for humanization, wherein the humanization process comprises searching and transplanting mainly for a human template.

The main goal of humanization engineering is the FR sequence in the variable region. The amino acids of the VH and VL of the murine antibody 066-7.17.2 are used as templates, sequence alignment is carried out on NCBI website, 5 humanized reference sequences are found, and the humanized modified sequences are designed as the reference templates for humanized modification of the FR regions of the antibody.

The specific sequences of the CDR regions are shown in Table 4, and the sequences of the humanized antibody after grafting of the remaining FR regions are shown in Table 5.

TABLE 4, 066-7.17.2 antibody CDR region specific sequences

TABLE 5, 066-7.17.2 antibody humanization sequences

>066-7.17.2H1(SEQ ID NO:25)

CAGGTGCAGCTGGTGGACAGCGGCGGCGGCGTGGTGCAGCCCGGCCGCAGCCTGCG CCTGAGCTGCGCCGCCAGCGACTTCGCCTTCCGCAGCTACGGCATGCACTGGGTGCG CCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCATGATCTGGTACGACGGCACCA AGAAGTACTACAGCGACAGCGTGAAGGGCCGCTTCACCATCAGCCGCGACAACAGC AAGAACACCCTGTACCTGCAGATGAACACCCTGCGCGCCGAGGACACCGCCGTGTA CTACTGCGCCCGCGACCGCGGCATCGGCACCCGCCACGGCCCCTACTTCATGGACGT GTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC

>066-7.17.2H2(SEQ ID NO:26)

CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCGGCAGCCTGCG CCTGAGCTGCGCCGCCAGCGACTTCGCCTTCCGCAGCTACGGCATGCACTGGGTGCG CCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCATGATCTGGTACGACGGCACCA AGAAGTACTACAGCGACAGCGTGAAGGGCCGCTTCACCATCAGCCGCGACAACAGC AAGAACACCCTGTACCTGCAGATGAACACCCTGCGCGCCGAGGACACCGCCGTGTA CTACTGCGCCAAGGACCGCGGCATCGGCACCCGCCACGGCCCCTACTTCATGGACGT GTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC

>066-7.17.2H3(SEQ ID NO:27)

CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCCGCAGCCTGCG CCTGAGCTGCGCCGCCAGCGACTTCGCCTTCCGCAGCTACGGCATGCACTGGGTGCG CCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCATGATCTGGTACGACGGCACCA AGAAGTACTACAGCGACAGCGTGAAGGGCCGCTTCACCATCAGCCGCGACAACAGC AAGAACACCCTGTACCTGCAGATGAACACCCTGCGCGCCGAGGACACCGCCGTGTA CTACTGCGCCCGCGACCGCGGCATCGGCACCCGCCACGGCCCCTACTTCATGGACGT GTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC

>066-7.17.2H4(SEQ ID NO:28)

GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGCG CCTGAGCTGCGCCGCCAGCGACTTCGCCTTCCGCAGCTACGGCATGCACTGGGTGCG CCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCATGATCTGGTACGACGGCACCA AGAAGTACTACAGCGACAGCGTGAAGGGCCGCTTCACCATCAGCCGCGACAACAGC AAGAACACCCTGTACCTGCAGATGAACACCCTGCGCGCCGAGGACACCGCCGTGTA CTACTGCGCCAAGGACCGCGGCATCGGCACCCGCCACGGCCCCTACTTCATGGACGT GTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC

>066-7.17.2H5(SEQ ID NO:29)

GAGGTGCAGCTGGTGGAGAGCGGCGGCGTGGTGGTGCAGCCCGGCGGCAGCCTGCG CCTGAGCTGCGCCGCCAGCGACTTCGCCTTCCGCAGCTACGGCATGCACTGGGTGCG CCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCATGATCTGGTACGACGGCACCA AGAAGTACTACAGCGACAGCGTGAAGGGCCGCTTCACCATCAGCCGCGACAACAGC AAGAACAGCCTGTACCTGCAGATGAACACCCTGCGCACCGAGGACACCGCCCTGTA CTACTGCGCCAAGGACCGCGGCATCGGCACCCGCCACGGCCCCTACTTCATGGACGT GTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC

>066-7.17.2L1(SEQ ID NO:30)

AACATCCAGATGACCCAGAGCCCCAGCGCCATGAGCGCCAGCGTGGGCGACCGCGT GACCATCACCTGCCACGCCCGCCACAACGTGCGCAGCTACCTGAACTGGTTCCAGCA GAAGCCCGGCAAGGTGCCCAAGCACCTGATCTACGCCGCCAGCAGCCAGCAGCGCG GCGTGCCCAGCCGCTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATC AGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCTGCAGAGCTTCGGCACC CCCCTGACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG

>066-7.17.2L2(SEQ ID NO:31)

GACATCCAGATGACCCAGAGCCCCAGCTTCCTGAGCGCCAGCGTGGGCGACCGCGT GACCATCACCTGCCACGCCCGCCACAACGTGCGCAGCTACCTGAACTGGTACCAGC AGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAGCCAGCAGCGC GGCGTGCCCAGCCGCTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCAT CAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCTGCAGAGCTTCGGCAC CCCCCTGACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG

>066-7.17.2L3(SEQ ID NO:32)

GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACCGCGT GACCATCACCTGCCACGCCCGCCACAACGTGCGCAGCTACCTGAACTGGTACCAGC AGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAGCCAGCAGCGC GGCGTGCCCAGCCGCTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATC AGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCTGCAGAGCTTCGGCAC CCCCCTGACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG

>066-7.17.2L4(SEQ ID NO:33)

GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACCGCGT GACCATCACCTGCCACGCCCGCCACAACGTGCGCAGCTACCTGAACTGGTACCGCC AGAAGCCCGGCAAGGTGCCCAAGCTGCTGATCTACGCCGCCAGCAGCCAGCAGCGC GGCGTGCCCAGCCGCTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCAT CAGCAGCCTGCAGCCCGAGGACGTGGCCACCTACTACGGCCTGCAGAGCTTCGGCA CCCCCCTGACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG

>066-7.17.2L5(SEQ ID NO:34)

GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACCGCGT GACCATCACCTGCCACGCCCGCCACAACGTGCGCAGCTACCTGAACTGGTACCAGC AGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAGCCAGCAGCGC GGCGTGCCCAGCCGCTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCAT CAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCTGCAGAGCTTCGGCAC CCCCCTGACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG

Example 9 preparation of humanized full-length antibody of A.beta.

1. Construction of full-Length antibody transient transfection expression vector

pGS003-hIgG1CH and pGS003-hIgKCL were selected as expression vectors for constructing heavy and light chains of anti-human Abeta full-length antibodies, respectively. The 066-7.17.2 humanized antibody sequence was codon optimized, PCR amplified, with Hind III and Nhe I for the heavy chain and Hind III and Nar I for the light chain, and 5 VH and 5 VL antibody genes cloned into pGS003-hIgG1CH and pGS003-hIgKCL, respectively, as shown in Table 6. After sequencing to identify the correct insertion of the antibody gene, the recombinant expression vector was transformed into E.coli TOP 10F', and a single colony was picked and inoculated into LB medium containing 100. mu.g/ml ampicillin and cultured with shaking at 37 ℃ for 16 hours. The plasmid was extracted using a Zymo Research endotoxin removal large scale kit, and finally dissolved in 1ml of ultrapure water, and the plasmid concentration and OD were measured with a spectrophotometer_260/280。 OD_260/280The plasmid DNA with high purity is 1.8-1.9.

TABLE 6 list of heavy and light chain transient transfection expression vectors

2. Transfection, expression and detection in mammalian cells 293E

After the 5 heavy chain expression vectors and the 5 light chain expression vectors of 066-7.17.2 are respectively combined in pairs (25 combinations in total), transient transfection expression evaluation of a 2ml 293E system is carried out, expression quantity and ELISA value evaluation are carried out on the 25 combinations, specific values are shown in Table 7, 6 full-length antibodies are preferably selected, and the specific values are 066-7.17.2-H1L5, 066-7.17.2-H2L3, 066-7.17.2-H2L5, 066-7.17.2-H3L5, 066-7.17.2-H4L5 and 066-7.17.2-H5L 5.

TABLE 7, 066-7.17.2 expression level of transient transfection expression of humanized 5X 5 combined full-length antibody minibody line and EC50 detection value

Note: in the table, "- -" indicates no binding and "ND" indicates no detection.

Transient transfection expression of 6 candidate antibodies was performed using 293E in Freestyle medium. 24 hours before transfection, 0.5X 10 cells were inoculated into 1L cell culture flasks⁶Cell/ml 293E cells 300ml, 5% CO at 37 ℃₂Shaking and culturing at 120rpm in an incubator. When in transfection, 300 mu l of 293fectin is firstly added into 5.7ml of Opti-MEM, and after fully mixing, the mixture is incubated for 2 minutes at room temperature; at the same time, 300. mu.g of each of the heavy and light chain expression plasmids was diluted to 6ml using Opti-MEM. Mixing the diluted transfection reagent and plasmid, incubating at room temperature for 15 min, adding the mixture into cells, mixing, and adding 5% CO at 37 deg.C₂Shaking at 120rpm in incubator for 7 days.

3. Purification and detection of antibodies

The cell culture broth was centrifuged at 2000g for 20min, the supernatant was collected, and the amount of antibody expression in the supernatant was determined by Octet, see Table 8.

TABLE 8, 6 detection of expression level of 300ml transient transfection expression of candidate antibody

Name of antibody	Heavy chain sequence	Light chain sequence	Transient transfection expression amount (mg/L)
				066-7.17.2H1L5	066-7.17.2H1	066-7.17.2L5	41.7
066-7.17.2H2L3	066-7.17.2H2	066-7.17.2L3	56.5
				066-7.17.2H2L5	066-7.17.2H2	066-7.17.2L5	36.6
066-7.17.2H3L5	066-7.17.2H3	066-7.17.2L5	42.4
				066-7.17.2H4L5	066-7.17.2H4	066-7.17.2L5	31
066-7.17.2H5L5	066-7.17.2H5	066-7.17.2L5	28

The supernatant was filtered through a 0.22 micron filter, then passed through a MabSelect Sure affinity chromatography column (GE), 20mM citric acid-sodium citrate, pH 3.0, eluted, pH adjusted to neutral with 1M Tris base, and adjusted to an isotonic solution by addition of 10 XPBS. Protein was purified by SDS-PAGE using 4-20% gradient gel (Biotech, GmbH, King-Shirui, Nanjing), and the results are shown in FIG. 10.

Example 10 determination of humanized candidate antibody EC50 values

Coating: the mixture of human Abeta 42 monomer and polymer is diluted to 1 mu g/ml by CBS (pH 9.4), added into 96 wells of an ELISA plate with 50 mu l per well, and incubated overnight at 2-8 ℃.

And (3) sealing: after three washes with PBST, the plates were blocked with 3% BSA and incubated at 200. mu.l/well for 1 hour at 25 ℃.

Sample treatment: humanized candidate antibody and chimeric antibody were each diluted 2-fold with a gradient of 10. mu.g/ml as the starting concentration (2)⁰～2^-11) 50 μ l/well, incubated for 1h at 25 ℃.

Adding an antibody: after washing the plate four times with PBST, anti-human IgG (H + L) -HRP antibody, 1:5000 dilution, 50. mu.l/well, was added and incubated for 1H at 25 ℃.

Color development: after washing the plate four times, adding TMB developing solution, 50 μ l per well, and developing for 3 minutes in the dark at room temperature.

Data processing: the raw data were input into the software SoftMax Pro 6.2.1 for data processing. The data are shown in Table 9. The results showed that 6 humanized candidate antibodies had binding ability to human a β comparable to that of the chimeric antibody.

TABLE 9, 6 candidate antibody and antigen binding EC50 values

Note: in the table, "- -" indicates no binding and "ND" indicates no detection.

EXAMPLE 11 determination of KD values for humanized candidate antibodies

Biacore-T200 detection is applied, a ProteinA chip is used for capturing candidate antibodies or positive antibodies, human Abeta antigens with different concentrations flow through the chip, and fitting analysis is carried out according to collected data. Antigen samples were diluted in a 2-fold concentration gradient using HBS-EP + Buffer to 400nmol/L, 200nmol/L, 100nmol/L, 50nmol/L, 25nmol/L, 12.5nmol/L, 6.25nmol/L, 3.125nmol/L, 1.56nmol/L, 0.78nmol/L, 0nmol/L concentration gradient solutions. Samples were tested at a repeat concentration of 25 nmol/L. The detection conditions are as follows: a capture time of 30 s; antigen binding time 120 s; the dissociation time is 900 s; flow rate 30. mu.l/min, regeneration conditions 20mM NaOH solution, flow rate: 30 μ l/min. The results of the specific experiments are shown in Table 10. From the experimental results, it can be seen that the KD value of the humanized antibody can be maintained at a level comparable to that of the murine antibody, relative to that of the murine human chimeric antibody.

TABLE 10, 6 candidate antibody KD value detection

Name of antibody	Ka(1/Ms)	Kd(1/s)	KD(M)
				066-7.17.2H1L5	2.38E+04	1.03E-04	4.32E-09
066-7.17.2H2L3	4.80E+04	2.74E-04	5.70E-09
				066-7.17.2H2L5	1.30E+04	3.60E-04	2.76E-09
066-7.17.2H3L5	1.51E+04	2.33E-04	1.54E-09
				066-7.17.2H4L5	3.55E+04	1.91E-04	5.37E-09
066-7.17.2H5L5	3.42E+04	1.92E-04	5.61E-09
				066-7.17.2-chAb	2.33E+04	7.02E-04	3.01E-09

Note: e + 04: x 10⁴；E-04：×10^-4；E-09：×10^-09。

Example 12 detection of macrophage phagocytosis of A.beta.Activity by humanized A.beta.antibody

Mouse primary abdominal cavity macrophage with good adherence for 3 days, digesting with 0.25% trypsin, counting, and adjusting cell density to 2 × 10 with DMEM culture medium (Gibco) containing 10% serum fetal bovine serum⁵Seed 96-well cell culture plate in 100. mu.l/well; a working solution was prepared by diluting 066-7.17.2 humanized candidate antibody to 20. mu.g/ml in DMEM medium containing 1% fetal bovine serum, diluting A.beta.to 240. mu.g/ml, and diluting ThT (sigma) to 20. mu.M in ultrapure water. Discarding the culture medium in the culture plate, adding 50 μ l of candidate antibody diluent, adding 50 μ lA β diluent, and setting multiple wells; 37 ℃ and 5% CO₂Culturing for 6 hours in an incubator; 50. mu.l of the supernatant was put into a 96-well blackboard, and 50. mu.l of ThT was added thereto, and the fluorescence intensity was measured by a multifunctional microplate reader (Ex/Em. 440/485). The abscissa represents the different sample addition groups, and the ordinate represents the fluorescence intensity, and the results are shown in FIG. 11. The relative fluorescence intensity of hIgG was 1.00, that of 066-7.17.2-mAb group was 0.47, that of 066-7.17.2-chop group was 0.54, that of 066-7.17.2H1L5 group was 0.51, that of 066-7.17.2H2L3 group was 0.55, that of 066-7.17.2H2L5 group was 0.63, that of 066-7.17.2H3L5 group was 0.44, that of 066-7.17.2H4L5 group was 0.44, and that of 066-7.17.2H5L5 group was 0.42. It can be seen that the 066-7.17.2 humanized candidate antibodies all have the activity of promoting macrophage phagocytosis of A beta.

Example 13 assay of humanized A β antibody cytotoxic protective Activity

Logarithmic growth phase SHSY5Y cells, digested with 0.25% trypsin, counted, and adjusted to 3X 10 cell density with EMEM culture medium (ATCC) containing 10% fetal bovine serum⁴Seed 96-well cell culture plate in 100. mu.l/well; the humanized candidate antibody was diluted 066-7.17.2 to 200. mu.g/ml (IC100) in EMEM medium with 1% fetal bovine serum as a working solution, and A.beta.was diluted to 240. mu.g/ml. Discarding the culture medium in the culture plate, adding 50 μ l of candidate antibody diluent, adding 50 μ l A β diluent, and setting multiple wells; culturing at 37 deg.C in 5% CO2 incubator for 48 hr; adding 50 μ l of supernatant into a new 96-well plate, and addingAdding 50 μ l LDH assay buffer, keeping out of the sun at room temperature for 30min, adding 50 μ l stop solution, and detecting the light absorption value with a multifunctional microplate reader. The abscissa is the different loading groups and the ordinate is the relative value of LDH release, and the results are shown in FIG. 12. The relative value of LDH release of Vehicle is 1.00, the relative value of LDH release of 066-P02 group is 1.47, the relative value of LDH release of 066-7.17.2-mAb group is 1.43, the relative value of LDH release of 066-7.17.2-ChAb group is 1.40, the relative value of LDH release of 066-7.17.2H1L5 group is 1.30, the relative value of LDH release of 066-7.17.2H2L3 group is 1.52, the relative value of LDH release of 066-7.17.2H2L5 group is 1.29, the relative value of LDH release of 066-7.17.2H3L5 group is 1.00, the relative value of LDH release of 066-7.17.2H4L5 group is 1.31, and the relative value of LDH release of 066-7.17.2H5L5 group is 1.41. It can be seen that the 066-7.17.2 humanized candidate antibodies all have cytotoxic protection effects, and the protection effects are equivalent to 066-P02, wherein 066-7.17.2H3L5 performs optimally.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Sequence listing

<110> Changchun golden race pharmaceutical Limited liability company

<120> humanized anti-Abeta monoclonal antibody and application thereof

<130> MP1828745

<160> 51

<170> SIPOSequenceListing 1.0

<210> 1

<211> 5

<212> PRT

<213> CDR region of heavy chain (CDR region of heavy chain)

<400> 1

Ser Tyr Gly Met His

1 5

<210> 2

<211> 17

<212> PRT

<213> CDR region of heavy chain (CDR region of heavy chain)

<400> 2

Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val Lys

1 5 10 15

Gly

<210> 3

<211> 15

<212> PRT

<213> CDR region of heavy chain (CDR region of heavy chain)

<400> 3

Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp Val

1 5 10 15

<210> 4

<211> 10

<212> PRT

<213> CDR region of light chain (CDR region of the light chain)

<400> 4

His Ala Arg His Asn Val Arg Ser Tyr Leu

1 5 10

<210> 5

<211> 7

<212> PRT

<213> CDR region of light chain (CDR region of the light chain)

<400> 5

Ala Ala Ser Ser Gln Gln Arg

1 5

<210> 6

<211> 9

<212> PRT

<213> CDR region of light chain (CDR region of the light chain)

<400> 6

Leu Gln Ser Phe Gly Thr Pro Leu Thr

1 5

<210> 7

<211> 30

<212> PRT

<213> FR region of heavy chain (FR region of heavy chain)

<400> 7

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Arg

20 25 30

<210> 8

<211> 14

<212> PRT

<213> FR region of heavy chain (FR region of heavy chain)

<400> 8

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala

1 5 10

<210> 9

<211> 32

<212> PRT

<213> FR region of heavy chain (FR region of heavy chain)

<400> 9

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln

1 5 10 15

Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg

20 25 30

<210> 10

<211> 11

<212> PRT

<213> FR region of heavy chain (FR region of heavy chain)

<400> 10

Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

1 5 10

<210> 11

<211> 23

<212> PRT

<213> FR region of light chain (FR region of light chain)

<400> 11

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys

20

<210> 12

<211> 15

<212> PRT

<213> FR region of light chain (FR region of light chain)

<400> 12

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr

1 5 10 15

<210> 13

<211> 32

<212> PRT

<213> FR region of light chain (FR region of light chain)

<400> 13

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys

20 25 30

<210> 14

<211> 10

<212> PRT

<213> FR region of light chain (FR region of light chain)

<400> 14

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

1 5 10

<210> 15

<211> 124

<212> PRT

<213> 066-7.17.2 H1

<400> 15

Gln Val Gln Leu Val Asp Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Arg Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 16

<211> 124

<212> PRT

<213> 066-7.17.2 H2

<400> 16

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Arg Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 17

<211> 124

<212> PRT

<213> 066-7.17.2 H3

<400> 17

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Arg Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 18

<211> 124

<212> PRT

<213> 066-7.17.2 H4

<400> 18

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Arg Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 19

<211> 124

<212> PRT

<213> 066-7.17.2 H5

<400> 19

Glu Val Gln Leu Val Glu Ser Gly Gly Val Val Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Arg Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Ala Lys Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 20

<211> 107

<212> PRT

<213> 066-7.17.2 L1

<400> 20

Asn Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys His Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 21

<211> 107

<212> PRT

<213> 066-7.17.2 L2

<400> 21

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 22

<211> 107

<212> PRT

<213> 066-7.17.2 L3

<400> 22

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 23

<211> 107

<212> PRT

<213> 066-7.17.2 L4

<400> 23

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Tyr Arg Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Gly Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 24

<211> 107

<212> PRT

<213> 066-7.17.2 L5

<400> 24

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 25

<211> 372

<212> DNA

<213> 066-7.17.2 H1

<400> 25

caggtgcagc tggtggacag cggcggcggc gtggtgcagc ccggccgcag cctgcgcctg 60

agctgcgccg ccagcgactt cgccttccgc agctacggca tgcactgggt gcgccaggcc 120

cccggcaagg gcctggagtg ggtggccatg atctggtacg acggcaccaa gaagtactac 180

agcgacagcg tgaagggccg cttcaccatc agccgcgaca acagcaagaa caccctgtac 240

ctgcagatga acaccctgcg cgccgaggac accgccgtgt actactgcgc ccgcgaccgc 300

ggcatcggca cccgccacgg cccctacttc atggacgtgt ggggcaaggg caccaccgtg 360

accgtgagca gc 372

<210> 26

<211> 372

<212> DNA

<213> 066-7.17.2 H2

<400> 26

caggtgcagc tggtggagag cggcggcggc gtggtgcagc ccggcggcag cctgcgcctg 60

agctgcgccg ccagcgactt cgccttccgc agctacggca tgcactgggt gcgccaggcc 120

cccggcaagg gcctggagtg ggtggccatg atctggtacg acggcaccaa gaagtactac 180

agcgacagcg tgaagggccg cttcaccatc agccgcgaca acagcaagaa caccctgtac 240

ctgcagatga acaccctgcg cgccgaggac accgccgtgt actactgcgc caaggaccgc 300

ggcatcggca cccgccacgg cccctacttc atggacgtgt ggggcaaggg caccaccgtg 360

accgtgagca gc 372

<210> 27

<211> 372

<212> DNA

<213> 066-7.17.2 H3

<400> 27

caggtgcagc tggtggagag cggcggcggc gtggtgcagc ccggccgcag cctgcgcctg 60

agctgcgccg ccagcgactt cgccttccgc agctacggca tgcactgggt gcgccaggcc 120

cccggcaagg gcctggagtg ggtggccatg atctggtacg acggcaccaa gaagtactac 180

agcgacagcg tgaagggccg cttcaccatc agccgcgaca acagcaagaa caccctgtac 240

ctgcagatga acaccctgcg cgccgaggac accgccgtgt actactgcgc ccgcgaccgc 300

ggcatcggca cccgccacgg cccctacttc atggacgtgt ggggcaaggg caccaccgtg 360

accgtgagca gc 372

<210> 28

<211> 372

<212> DNA

<213> 066-7.17.2 H4

<400> 28

gaggtgcagc tgctggagag cggcggcggc ctggtgcagc ccggcggcag cctgcgcctg 60

agctgcgccg ccagcgactt cgccttccgc agctacggca tgcactgggt gcgccaggcc 120

cccggcaagg gcctggagtg ggtgagcatg atctggtacg acggcaccaa gaagtactac 180

agcgacagcg tgaagggccg cttcaccatc agccgcgaca acagcaagaa caccctgtac 240

ctgcagatga acaccctgcg cgccgaggac accgccgtgt actactgcgc caaggaccgc 300

ggcatcggca cccgccacgg cccctacttc atggacgtgt ggggcaaggg caccaccgtg 360

accgtgagca gc 372

<210> 29

<211> 372

<212> DNA

<213> 066-7.17.2 H5

<400> 29

gaggtgcagc tggtggagag cggcggcgtg gtggtgcagc ccggcggcag cctgcgcctg 60

agctgcgccg ccagcgactt cgccttccgc agctacggca tgcactgggt gcgccaggcc 120

cccggcaagg gcctggagtg ggtgagcatg atctggtacg acggcaccaa gaagtactac 180

agcgacagcg tgaagggccg cttcaccatc agccgcgaca acagcaagaa cagcctgtac 240

ctgcagatga acaccctgcg caccgaggac accgccctgt actactgcgc caaggaccgc 300

ggcatcggca cccgccacgg cccctacttc atggacgtgt ggggcaaggg caccaccgtg 360

accgtgagca gc 372

<210> 30

<211> 321

<212> DNA

<213> 066-7.17.2 L1

<400> 30

aacatccaga tgacccagag ccccagcgcc atgagcgcca gcgtgggcga ccgcgtgacc 60

atcacctgcc acgcccgcca caacgtgcgc agctacctga actggttcca gcagaagccc 120

ggcaaggtgc ccaagcacct gatctacgcc gccagcagcc agcagcgcgg cgtgcccagc 180

cgcttcagcg gcagcggcag cggcaccgag ttcaccctga ccatcagcag cctgcagccc 240

gaggacttcg ccacctacta ctgcctgcag agcttcggca cccccctgac cttcggcggc 300

ggcaccaagg tggagatcaa g 321

<210> 31

<211> 321

<212> DNA

<213> 066-7.17.2 L2

<400> 31

gacatccaga tgacccagag ccccagcttc ctgagcgcca gcgtgggcga ccgcgtgacc 60

atcacctgcc acgcccgcca caacgtgcgc agctacctga actggtacca gcagaagccc 120

ggcaaggccc ccaagctgct gatctacgcc gccagcagcc agcagcgcgg cgtgcccagc 180

cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc 240

gaggacttcg ccacctacta ctgcctgcag agcttcggca cccccctgac cttcggcggc 300

ggcaccaagg tggagatcaa g 321

<210> 32

<211> 321

<212> DNA

<213> 066-7.17.2 L3

<400> 32

gacatccaga tgacccagag ccccagcagc ctgagcgcca gcgtgggcga ccgcgtgacc 60

atcacctgcc acgcccgcca caacgtgcgc agctacctga actggtacca gcagaagccc 120

ggcaaggccc ccaagctgct gatctacgcc gccagcagcc agcagcgcgg cgtgcccagc 180

cgcttcagcg gcagcggcag cggcaccgac ttcaccttca ccatcagcag cctgcagccc 240

gaggacatcg ccacctacta ctgcctgcag agcttcggca cccccctgac cttcggcggc 300

ggcaccaagg tggagatcaa g 321

<210> 33

<211> 321

<212> DNA

<213> 066-7.17.2 L4

<400> 33

gacatccagc tgacccagag ccccagcagc ctgagcgcca gcgtgggcga ccgcgtgacc 60

atcacctgcc acgcccgcca caacgtgcgc agctacctga actggtaccg ccagaagccc 120

ggcaaggtgc ccaagctgct gatctacgcc gccagcagcc agcagcgcgg cgtgcccagc 180

cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc 240

gaggacgtgg ccacctacta cggcctgcag agcttcggca cccccctgac cttcggcggc 300

ggcaccaagg tggagatcaa g 321

<210> 34

<211> 321

<212> DNA

<213> 066-7.17.2 L5

<400> 34

gacatccaga tgacccagag ccccagcagc ctgagcgcca gcgtgggcga ccgcgtgacc 60

atcacctgcc acgcccgcca caacgtgcgc agctacctga actggtacca gcagaagccc 120

ggcaaggccc ccaagctgct gatctacgcc gccagcagcc agcagcgcgg cgtgcccagc 180

cgcttcagcg gcagcggcag cggcaccgac ttcaccctga ccatcagcag cctgcagccc 240

gaggacttcg ccacctacta ctgcctgcag agcttcggca cccccctgac cttcggcggc 300

ggcaccaagg tggagatcaa g 321

<210> 35

<211> 42

<212> PRT

<213> Aβ1-42

<400> 35

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala

35 40

<210> 36

<211> 16

<212> PRT

<213> Aβ1-16

<400> 36

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1 5 10 15

<210> 37

<211> 17

<212> PRT

<213> Aβ14-29

<400> 37

His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly

1 5 10 15

Ala

<210> 38

<211> 112

<212> PRT

<213> 066-P01 Positive antibody heavy chain variable region (heavy chain variable region of 066-P01 positive antibody)

<400> 38

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr

20 25 30

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val

35 40 45

Ala Gln Ile Asn Ser Val Gly Asn Ser Thr Tyr Tyr Pro Asp Thr Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Ser Gly Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

100 105 110

<210> 39

<211> 112

<212> PRT

<213> 066-P01 Positive antibody light chain variable region (light chain variable region of 066-P01 positive antibody)

<400> 39

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly

1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Ile Tyr Ser

20 25 30

Asp Gly Asn Ala Tyr Leu His Trp Phe Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser

85 90 95

Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 40

<211> 124

<212> PRT

<213> 066-P02 Positive antibody heavy chain variable region (heavy chain variable region of 066-P02 positive antibody)

<400> 40

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Val Ile Trp Phe Asp Gly Thr Lys Lys Tyr Tyr Thr Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Arg Gly Ile Gly Ala Arg Arg Gly Pro Tyr Tyr Met Asp

100 105 110

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 41

<211> 107

<212> PRT

<213> 066-P02 Positive antibody light chain variable region (light chain variable region of 066-P02 positive antibody)

<400> 41

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 42

<211> 21

<212> DNA

<213> mIgGR

<400> 42

ctcagggaar tarccyttga c 21

<210> 43

<211> 21

<212> DNA

<213> mIgKR

<400> 43

tcactgccat caatcttcca c 21

<210> 44

<211> 18

<212> DNA

<213> M13F

<400> 44

tgtaaaacga cggccagt 18

<210> 45

<211> 18

<212> DNA

<213> M13R

<400> 45

caggaaacag ctatgacc 18

<210> 46

<211> 372

<212> DNA

<213> Heavy chain variable region of 066-7.17.2 antibody (Heavy chain variable region of 066-7.17.2 antibody)

<400> 46

gaggtgcagc tggtggagag cggcggcggc ctggtgaagc ccggcggcag cctgaagctg 60

agctgcgccg ccagcggctt caccttcagc agctacggca tgcactgggt gaggcaggcc 120

cccgagaagg gcctggagtg ggtggccatg atctggtacg acggcaccaa gaagtactac 180

agcgacagcg tgaagggcag gttcaccatc agcagggaca acgccaagaa caccctgttc 240

ctgcagatga ccagcctgag gagcgaggac accgccatgt actactgcgc cagggacagg 300

ggcatcggca ccaggcacgg cccctacttc atggacgtgt ggggccaggg caccagcgtg 360

accgtgagca gc 372

<210> 47

<211> 321

<212> DNA

<213> Light chain variable region of 066-7.17.2 antibody (Light chain variable region of 066-7.17.2 antibody)

<400> 47

gacatccaga tgaaccagag ccccagcagc ctgagcgcca gcctgggcga caccatcacc 60

atcacctgcc acgccaggca caacgtgagg agctacctga actggtacca gcagaagccc 120

ggcaacatcc ccaagctgct gatctacgcc gccagcagcc agcagagggg cgtgcccagc 180

aggttcagcg gcagcggcag cggcaccggc ttcaccctga ccatcagcag cctgcagccc 240

gaggacatcg ccacctacta ctgcctgcag agcttcggca cccccctgac cttcggcggc 300

ggcaccaagc tggagatcaa g 321

<210> 48

<211> 124

<212> PRT

<400> 48

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val

35 40 45

Ala Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe

65 70 75 80

Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys

85 90 95

Ala Arg Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

115 120

<210> 49

<211> 107

<212> PRT

<400> 49

Asp Ile Gln Met Asn Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Thr Ile Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 50

<211> 453

<212> PRT

<213> 066-7.17.2 heavy chain of murine human chimeric antibody (heavy chain of 066-7.17.2 murine polymeric antibody)

<400> 50

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val

35 40 45

Ala Met Ile Trp Tyr Asp Gly Thr Lys Lys Tyr Tyr Ser Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe

65 70 75 80

Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys

85 90 95

Ala Arg Asp Arg Gly Ile Gly Thr Arg His Gly Pro Tyr Phe Met Asp

100 105 110

Val Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys

115 120 125

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly

130 135 140

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro

145 150 155 160

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr

165 170 175

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val

180 185 190

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn

195 200 205

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro

210 215 220

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu

225 230 235 240

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp

245 250 255

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp

260 265 270

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly

275 280 285

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn

290 295 300

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp

305 310 315 320

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro

325 330 335

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu

340 345 350

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn

355 360 365

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile

370 375 380

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr

385 390 395 400

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys

405 410 415

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys

420 425 430

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu

435 440 445

Ser Leu Ser Pro Gly

450

<210> 51

<211> 214

<212> PRT

<213> 066-7.17.2 murine chimeric antibody light chain (light chain of 066-7.17.2 murine polymeric antibody)

<400> 51

Asp Ile Gln Met Asn Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Thr Ile Thr Ile Thr Cys His Ala Arg His Asn Val Arg Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Gln Gln Arg Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Ser Phe Gly Thr Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala

100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly

115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala

130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln

145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser

165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser

195 200 205

Phe Asn Arg Gly Glu Cys

210

Claims

1.A humanized anti-A beta monoclonal antibody characterized in that,

the amino acid sequences of CDR1-3 of the heavy chain of the monoclonal antibody are respectively shown as SEQ ID NO 1, 2 and 3; and the amino acid sequences of CDR1-3 of the light chain of the monoclonal antibody are respectively shown as SEQ ID NO. 4, 5 and 6.

2. The monoclonal antibody of claim 1,

FR1-4 of the heavy chain of the monoclonal antibody has amino acid sequences shown as SEQ ID NO 7, 8, 9 and 10 respectively; and FR1-4 of the light chain of the monoclonal antibody has the amino acid sequences shown in SEQ ID NO 11, 12, 13 and 14, respectively.

3. The monoclonal antibody of claim 1,

the heavy chain variable region has an amino acid sequence shown in any one of SEQ ID NO 15-19, and the light chain variable region has an amino acid sequence shown in any one of SEQ ID NO 20-24.

4. The monoclonal antibody of claim 1 or 3, wherein the epitopes of the monoclonal antibody are all human A β_1~16。

5. The monoclonal antibody of claim 1 or 3,

the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 15, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 24;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 16, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 22;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 16, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 24;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 17, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 24;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 18, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 24;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 19, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 24;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 15, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 20;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 15, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 21;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 15, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 22;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 15, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 23;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 16, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 20;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 16, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 21;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 16, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 23;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 17, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 20;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 17, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 21;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 17, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 22;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 17, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 23;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 18, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 20;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 18, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 21;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 18, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 22;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 18, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 23;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 19, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 20;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 19, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 21;

or the heavy chain variable region has an amino acid sequence shown as SEQ ID NO. 19, and the light chain variable region has an amino acid sequence shown as SEQ ID NO. 22;

or the heavy chain variable region has the amino acid sequence shown as SEQ ID NO. 19, and the light chain variable region has the amino acid sequence shown as SEQ ID NO. 23.

6. The monoclonal antibody of any one of claims 1-3, further comprising a constant region, the constant region of the heavy chain of the monoclonal antibody being any one of human IgG1, IgG2, IgG3, or IgG 4; the constant region of the light chain of the monoclonal antibody is of the kappa type or of the lambda type.

7. The monoclonal antibody of claim 4, further comprising a constant region, the constant region of the heavy chain of the monoclonal antibody being any one of human IgG1, IgG2, IgG3, or IgG 4; the constant region of the light chain of the monoclonal antibody is of the kappa type or of the lambda type.

8. The monoclonal antibody of claim 5, further comprising a constant region, the constant region of the heavy chain of the monoclonal antibody being any one of human IgG1, IgG2, IgG3, or IgG 4; the constant region of the light chain of the monoclonal antibody is of the kappa type or of the lambda type.

9. A nucleotide encoding the monoclonal antibody of any one of claims 1 to 8.

10. An expression vector comprising nucleotides encoding the monoclonal antibody of any one of claims 1-8.

11. A host cell transformed or transfected with the expression vector of claim 10.

12. A method of producing a monoclonal antibody as claimed in any one of claims 1 to 8, comprising: culturing the host cell of claim 11, and inducing expression of the humanized anti-a β monoclonal antibody.

13. A conjugate comprising a chemically or biologically labeled monoclonal antibody according to any one of claims 1-8.

14. A monoclonal antibody according to any one of claims 1 to 8 or a conjugate according to claim 13 conjugated to a solid or semi-solid medium.

15. Use of a monoclonal antibody according to any one of claims 1 to 8, a conjugate according to claim 13 and/or a conjugate according to claim 14 for the preparation of an agent against cognitive impairment, a therapeutic agent for alzheimer's disease, an agent for suppressing the progression of alzheimer's disease, an agent for inhibiting the formation of senile plaques, an agent for suppressing the accumulation of a β, an anti-neurotoxic agent, an agent for inhibiting the formation of a β amyloid fibrils and/or an agent against synaptic toxicity.

16. Use of a monoclonal antibody according to any one of claims 1 to 8, a conjugate according to claim 13 and/or a conjugate according to claim 14 for the manufacture of a medicament for the prevention or treatment of a disease; the disease comprises amyloidosis, including secondary amyloidosis and age-related amyloidosis, including neurological diseases including alzheimer's disease.

17. Medicament comprising a monoclonal antibody according to any one of claims 1 to 8, a conjugate according to claim 13 and/or a conjugate according to claim 14.

18. Use of a monoclonal antibody according to any one of claims 1 to 8, a conjugate according to claim 13 and/or a conjugate according to claim 14 for the preparation of a product for detecting expression of a β.

19. A kit comprising a monoclonal antibody according to any one of claims 1 to 8, a conjugate according to claim 13 and/or a conjugate according to claim 14.